REVIEW article

Front. Pharmacol., 19 June 2020

Sec. Ethnopharmacology

Volume 11 - 2020 | https://doi.org/10.3389/fphar.2020.00832

Phytochemicals: Potential Lead Molecules for MDR Reversal

  • 1. Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany

  • 2. Marine Sciences Faculty, Tarbiat Modares University, Noor, Iran

Article metrics

View details

74

Citations

9,1k

Views

2,6k

Downloads

Abstract

Multidrug resistance (MDR) is one of the main impediments in the treatment of cancers. MDR cancer cells are resistant to multiple anticancer drugs. One of the major mechanisms of MDR is the efflux of anticancer drugs by ABC transporters. Increased activity and overexpression of these transporters are important causes of drug efflux and, therefore, resistance to cancer chemotherapy. Overcoming MDR is a fundamental prerequisite for developing an efficient treatment of cancer. To date, various types of ABC transporter inhibitors have been employed but no effective anticancer drug is available at present, which can completely overcome MDR. Phytochemicals can reverse MDR in cancer cells via affecting the expression or activity of ABC transporters, and also through exerting synergistic interactions with anticancer drugs by addressing additional molecular targets. We have listed numerous phytochemicals which can affect the expression and activity of ABC transporters in MDR cancer cell lines. Phytochemicals in the groups of flavonoids, alkaloids, terpenes, carotenoids, stilbenoids, lignans, polyketides, and curcuminoids have been examined for MDR-reversing activity. The use of MDR-reversing phytochemicals with low toxicity to human in combination with effective anticancer agents may result in successful treatment of chemotherapy-resistant cancer. In this review, we summarize and discuss published evidence for natural products with MDR modulation abilities.

Introduction

Besides surgery and radiation, chemotherapy is one of the standard treatments of cancer. Drugs used in chemotherapy usually disturb cell division by inhibition of microtubule formation or disassembly (vinca alkaloids, paclitaxel), DNA topoisomerase (camptothecin and derivatives) or they intercalate or alkylate DNA (doxorubicin, cisplatin) (Wink, 2007; Wink et al., 2012). Furthermore, chemotherapy often causes extreme side effects as these drugs also affect the division of normal cells or they cause mutations, which can lead to secondary cancers. This additionally leads to restriction of the therapeutic applications; both dosage and application interval must be kept limited. When chemotherapeutic agents are used, it is often a matter of time before the cancer cells develop resistance against them. One of the major resistance mechanisms is the overexpression of ABC transporters, which can pump out the chemotherapeutic from cancer cells. Because these ABC transporters have a wide substrate spectrum, they not only confer resistance to a single drug but to several others, therefore, the term Multidrug Resistance (MDR). Since multiple drug resistance is a major issue in tumor therapy, new strategies are necessary to overcome this obstacle. One strategy involves the combination of anti-cancer drugs with modulators of ABC transporters. Our review presents a summary about various modulating effects of phytochemicals.

Multidrug Resistance in Cancer

One of the major difficulties in suppressing growth and survival of cancer cells is multidrug resistance. MDR is the resistance of cancer cells to various types of anticancer drugs which may have an intrinsic or acquired origin. Acquired resistance is induced after the administration of chemotherapy, whereas, intrinsic resistance already exists prior to drug application in cancer cells (Wang et al., 2019). Several mechanisms in cancer cells can lead to MDR (Coley, 2008). These include changes in target enzymes, such as DNA topoisomerases (Brown et al., 1995), alteration in microtubule-associated proteins (Zhang et al., 1998), mutations or changes in tubulin (Kamath et al., 2005; Wang and Cabral, 2005), alteration in microtubules (Kavallaris et al., 2001), mitotic arrest (Kamath et al., 2005), mutated protein p53 (O'Connor et al., 1997), disruption in DNA repair due to the damaging effect of an anticancer drug (Bernstein et al., 2002) and the impairment of apoptosis or genes involved in apoptosis and necrosis (Tanaka et al., 2000; Simstein et al., 2003).

A widespread mechanism of MDR is drug efflux via transmembrane transporters known as ATP-binding cassette transporters (ABC transporter). Overexpression of these transporters is the most important cause of drug resistance in many cancer cells. The family of ABC transporter proteins has 48 members in humans and far more in nature (Chen et al., 2016). The most well-known and widely-studied ABC transporters include P-Glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP). These transporters are expressed in healthy cells of various mammalian tissues having physiological tasks for translocating small molecules. They are found especially in intestinal epithelial cells, endothelial cells of blood capillaries and epithelia of renal proximal tubules being involved in the excretion and clearance of endogenous and exogenous cytotoxic substances (Borst et al., 2000; Durmus et al., 2015; Chen et al., 2016). ABC transporters evolved in nature millions of years ago to eliminate toxic phytochemicals that herbivores would obtain from their plant diet (Wink, 2007). Anticancer drugs also can be substrates of these transporters and if being considered as foreign they get exported to the extracellular space by cells expressing ABC transporters. Cancer cells which are not resistant to anticancer agents yet can develop the ability by overexpressing these transporters for saving themselves from the substances being toxic to them. This leads to an increased efflux, leading to low intracellular drug concentrations, insufficient to kill a cancer cell. Once this overexpression has occurred, the efflux also affects other chemotherapeutics and thus, makes the cancer cell resistant to chemotherapy (Coley, 2008; Durmus et al., 2015).

P-gp (ABCB1)

P-gp is a 170 kDa protein which is encoded by the MDR1 gene. This transporter is found in normal cells of various tissues including the brain, liver, kidney, gastrointestinal tract and pancreas. P-gp transports anticancer drugs such as paclitaxel, doxorubicin, daunorubicin, epirubicin, mitoxantrone, vincristine, and vinblastine against the concentration gradient using energy derived from hydrolysis of ATP (Chen et al., 2016). Chemotherapeutic agents can stimulate P-gp expression in cancer cells and thereby cause resistance to chemotherapy. Chemotherapy has been reported to increase the proportion of P-gp-expressing tumors by approximately 1.8-fold in breast cancer. Moreover, in patients with activated P-gp transporter in their tumors, the risk of failure of chemotherapy is 3 times higher than in patients who do not express P-gp transporter (Trock et al., 1997).

Multidrug Resistance Proteins (MRPs)

Another class of membrane transporters which causes MDR is MRPs. Nine members of this class have been identified so far (König et al., 2005; Coley, 2008). MRPs are found in normal cells of some mammalian tissues and expel drugs as a complex with glutathione, glucuronate, or sulfate (Borst et al., 2000; Coley, 2008). Among the MRP transporters, MRP1 (ABCC1) is the most important and most studied one regarding MDR. The MRP1 protein has a molecular weight of 190 kDa. Similar to P-gp, MRP1 expression has been reported to be considerably higher expressed in cancer cells after chemotherapy than before chemotherapy (Trock et al., 1997). Therefore, MRP1 enhances resistance to chemotherapy and to anticancer drugs such as doxorubicin, daunorubicin, epirubicin, vincristine, and vinblastine (Coley, 2008).

BCRP (ABCG2)

Breast cancer resistance protein, also called mitoxantrone transporter (MXR1), has a molecular weight of 72 kDa. BCRP is extensively expressed in MCF-7 breast cancer cells (Doyle et al., 1998). This protein is also expressed in other tissues including the liver, kidney, and intestine (Chen et al., 2016). The anticancer drugs doxorubicin, daunorubicin, epirubicin and mitoxantrone have been described as substrates of BCRP transporter (Coley, 2008). Thus, cancer cells overexpressing BCRP transporter become resistant to these drugs.

MDR Modulators

One of the essential requirements for developing better anti-cancer therapies is overcoming multidrug resistance. Much research has been carried out on cancer treatment and development of anticancer drugs in recent years but MDR to cytostatics is still a great impediment. Although our knowledge about the mechanisms of multidrug resistance has increased, there is no effective drug which can completely overcome or reverse resistance at non-toxic concentrations. Since ABC transporters play a fundamental role in resistance to chemotherapy, the ability to inhibit them in a combination with conventional treatments will greatly help to treat cancer (Chen et al., 2016).

Until now, different types of ABC transporter inhibitors have been examined. The use of the first generation of these compounds, including verapamil and cyclosporine A, in combination with anticancer drugs had poor clinical success and toxic effects (Daenen et al., 2004). Second generation of MDR modulators included dexverapamil, valspodar, and dexniguldipine. Even though less toxic and with a higher therapeutic index than the first generation, this group of modulators is not well suited for a therapy either, both because of its interactions with other drugs and ABC transporters, as well as due to the inhibition of enzymes like CYP3A (Wandel et al., 1999; Syed and Coumar, 2016). The third-generation ABC transporter modulators do not have the disadvantages of the first and second generation. They are potent and non-competitive inhibitors of P-gp, and also less toxic. Tariquidar (XR9576) and zosuquidar are members of the third generation of MDR modulators but unfortunately they were not efficative in clinical trials (Cripe et al., 2010; Kelly et al., 2011).

Phytochemicals

Alkaloids (Figure 1) are the most widely studied group of secondary metabolites in terms of MDR, not only because of their quantity but also because of their great diversity (Wink, 2007; Wink et al., 2012). As alkaloids have a wide distribution among angiosperms (Wink, 2020) and represent a diversity of structures, they differ in pharmacological and toxicological properties. Alkaloids contain heterocyclic nitrogen, which mostly has its origin in amino acids (Cseke et al., 2006). Alkaloids are subdivided into many subcategories of special functional groups, similarities of skeleton or biosynthetic pathways.

Figure 1

Figure 1

Chemical structures of some selected alkaloids with MDR reversal effects.

Quinoline and isoquinoline alkaloids for example have a benzopyridine ring differing in the position of their nitrogen. Quinazoline alkaloids have a similar aromatic structure but with two nitrogen atoms instead of one. Each of these structures has found several uses depending on molecular structure. There are many examples for quinoline alkaloids such as mefloquine as antimalarial agent, fluoroquinolone antibiotics and topotecan as anticancer drug, just to name a few (Collin and Höke, 2000; Tiwary et al., 2015). The latter two work as inhibitors of different DNA topoisomerases (Lemmer and Brune, 2004).

Quinolizidines also are cyclic nitrogen-containing compounds but unlike the previously mentioned subgroups they are not aromatic. A natural representative is sparteine, which is used as an antiarrhythmic agent blocking sodium channels (Ruenitz and Mokler, 1977; Körper et al., 1998; Gawali et al., 2017).

Among other groups of alkaloids, indole, monoterpene indole and β-carboline alkaloids show many pharmacological activities (Gilbert, 2001). A typical basic structure of β-carboline alkaloids consists of benzene fused with a five-membered pyrrole and is consequently similarly structured to some endogenous hormones and neurotransmitters such as serotonin and melatonin. In addition to benzene, the pyrrole ring of β-carboline is fused to a pyridine, another six-membered nitrogen-containing ring. This structure by itself is an inverse agonist of GABA-receptors, which involves psychological influence on humans (Aktories et al., 2017). Substrates among the indoles target many receptors, for example PDE-receptors e.g. by tadalafil, 5-HT receptors e.g. by naratriptane and HMG-CoA reductases e.g. by fluvastatin (Wink, 2000; de Sa et al., 2009). Several indole alkaloids have stimulant and hallucinogenic properties (Wink, 2000; Wink and van Wyk, 2008).

As the nitrogen of steroidal alkaloids does not originate from amino acids they belong to pseudoalkaloids. A member of steroidal alkaloids is the teratogenic cyclopamine, which can cause cyclopean eyes in vertebrates (Roberts and Wink, 1998; Incardona et al., 1998).

Piperidine and diketopiperazine are six-membered non-aromatic moieties in alkaloids whereby diketopiperazine is a cyclic dipeptide having two oppositely located nitrogen. Pyrazine has the same position of nitrogen, though aromatic. Here we also can find medicinal use of active ingredients such as the oxytocin antagonist retosiban and plinabulin which is still in clinical trial against multiple drug resistant non-small cell lung cancer (Borthwick and Liddle, 2011; Mohanlal et al., 2019).

Tropane alkaloids are widespread and their plants one of the oldest medicines to use because of spasmolytic, mydriatic and hallucinogenic properties (Wink and van Wyk, 2008; van Wyk and Wink, 2017). They contain a special bicyclic moiety which is made of a seven-membered ring and a nitrogen atom which is linked to its C-1 and C-5 and forms the second ring (Osman et al., 2013). Due to their spasmolytic effect nowadays we use tropane alkaloids such as scopolamine or atropine for digestive tract spastic conditions and for ophthalmological purposes (Kukula-Koch and Widelski, 2017).

The most popular alkaloid caffeine belongs to purine alkaloids, which are consumed by many people on all continents. Theobromine, theophylline and caffeine are common members found as main ingredients in chocolate, mate, cola, green and black tea or coffee (Baumann and Frischknecht, 1988). By inhibiting adenosine receptors and cAMP phosphodiesterase they can mediate a stimulant effect (van Wyk and Wink, 2017).

Flavonoids (Figure 2) are another complex but also often colored group of secondary metabolites. Unlike alkaloids, we can make a general statement about their common origin and basic skeleton. Flavonoids can be classified as polyphenols which share a common biosynthesis. They contain aromatic rings with phenolic hydroxyl groups. These phenolic hydroxyl groups can dissociate under physiological condition and form negatively charged phenolate ions. Because of these properties flavonoids and polyphenols can interact with proteins forming multiple hydrogen and ionic bonds (Wink, 2015). Flavonoids are widely distributed in plants and are responsible, inter alia, for their pollinator attracting colors, ultraviolet light protection, antioxidant and antimicrobial functions, and mediating symbiosis with bacteria. Including the main subgroups flavones, isoflavones, flavonols, flavanones, anthocyanins, chalcones and catechins, they derive from flavan, a benzopyran structure with a phenyl ring in position 2. Flavonoids with a phenyl ring in position 3 and 4 are called iso- and neoflavonoids, respectively. The variety of flavonoids comes from many functional groups and different states of oxidation of the heterocycle (Koes et al., 1994; Wink and van Wyk, 2008; Hänsel and Sticher, 2009). Although there has been a lot of research on the antioxidant capacity of flavonoids, the mechanism is not fully understood yet. Many studies have reported anti-inflammatory, anti-carcinogenic, anti-mutagenic, antiviral, anti-allergic and osteogenetic potentials of flavonoids in vitro. There is evidence, that polyphenols are also important for the pharmacological activity of many medicinal plants (van Wyk and Wink, 2017). Still there is a lack of information about how the necessary bioavailability is achieved in the human body as polyphenols are polar compounds (Panche et al., 2016). Most common representatives in food are luteolin and apigenin. Isoflavones are known for their estrogenic properties (Wink, 2015).

Figure 2

Figure 2

Chemical structures of some selected flavonoids with MDR reversal effects.

In addition to flavonoids, there are smaller but also important groups of polyphenols, for example stilbenoid with resveratrol as its main member known for its potential as anti-cancer (Huang et al., 2014), antioxidant and anti-aging agent (Alamolhodaei et al., 2017). Curcuminoids (Figure 3) have been widely studied and have been found to have many functions such as antioxidative, anti-cancer, anti-microbial and anti-inflammatory effects in humans. They can interact with many targets (Fantini et al., 2015).

Figure 3

Figure 3

Chemical structures of some selected curcuminoids with MDR reversal effects.

Terpenes (Figure 4) are widely distributed in plants, fungi and animals. They are composed of different numbers of isoprene units, forming mono- (C10), di- (C20), sesqui- (C15), tetra- (C40) and triterpenes (C30). Many mono- and sequiterpenes are volatile and aromatic and typical ingredient of essential oils. These compounds are often lipophilic and can thus modulate the fluidity and permeability of biomembranes in animals and microbes. Many plants with essential oil have been used in traditional medicine for treatment of microbial infections and inflammation (Wink, 2015; van Wyk and Wink, 2017).

Figure 4

Figure 4

Chemical structures of some selected terpenes with MDR reversal effects.

Known for their skin permeation enhancing ability, terpenes have been used as moieties of synthetic structures for topical use (Smith and Maibach, 1995). In vitro studies have shown anti-cancer, antimicrobial and antioxidant activities but for practice and use in humans this class of secondary metabolites must be further investigated (Lu et al., 2012; Cör et al., 2018). Squalene is a standard triterpene produced in plants and animals, and it is the precursor for steroid synthesis. Glycosides of steroids or triterpenes, so-called saponins have one or more polysaccharides attached saponins are amphiphilic and react as a detergent. They generally form stable foams and complex cholesterol in biomembranes. As a consequence, saponins can lyse biomembranes (Bloch, 1983). In traditional medicine they have been used for example as expectorants and anti-infectants (Wink, 2015). As effective components of vaccine adjuvants they enhance the cellular immune response (Sun et al., 2009).

Carotenoids are tetraterpenes with many conjugated double bonds. They often exhibit yellow to purple colors and can function as anti-oxidants and precursors for vitamin A.

As the name implies polyketides contain carbonyl groups positioned between methylene groups. Still they vary in shape and volume. Although they appear with an impressive structural variety, they have their source from the same biosynthetic pathway. The most famous members among drugs may be the antibiotic erythromycin or the antifungal amphotericin B.

Phytochemicals Modulating MDR Targeting ABC-Transporters

A considerable number of secondary metabolites, which affect ABC transporters has already been discovered (Table 1) and several of them will be discussed in the following; glaucine (an isoquinoline alkaloid) increased the efflux of substrates such as ADR and MTX in the P-gp over-expressing cell lines of MCF-7/ADR and reduced DOX resistance in Caco-2 and CEM/ADR5000 (Eid et al., 2013; Lei et al., 2013). Tetrandrine (a benzolisoquinoline alkaloid) also caused an inhibition of efflux in Caco-2 and CEM/ADR5000 cells (Sun and Wink, 2014). A 5-substituted derivative of it named PY35 was tested for the MDR reversal activity, and showed more MDR reversal than the natural compound in resistant K562/ADM and MCF-7/ADM cells (Cao et al., 2014). Hernandezine, a bisbenzyl-isoquinoline, is a potent inhibitor of P-gp in MDR19-HEK293 cells and was able to resensitize MDR19-HEK293 and KB-V-1 cells to DOX after entering the cell membrane (Hsiao et al., 2016). High MDR-reversing activities of the quinoline derivatives were linked to the presence of two aryl rings in the hydrophobic moiety, deviation of the aryl rings from a common plane, basicity of nitrogen atom in piperazine, as well as to the distance between the hydrophobic moiety and the basic nitrogen of piperazine which must be no less than 5 Å (Suzuki et al., 1997). The quinolyl group was also suggested to have a key role in the activity of quinolines, because substitution of a quinoline ring by a naphthyl ring or a phenyl ring resulted in the reduction of MDR-reversing activity of the compounds (Suzuki et al., 1997). Among indole alkaloids, antofine showed synergistic effects with PTX in A549-PA cells and overcame resistance to PTX (Kim et al., 2012). The β-carboline harmine reversed the resistance of MTX and CPT in MDA-MB-231 cells with BCRP as overexpressed transporter but it could not affect the P-gp over-expressing CEM/ADR5000 cells the same way in this study (Ma and Wink, 2010). Not only has harmine been tested in combination with DOX but also as three-drug-combination with DTN both of which showed here an increase of effect on cells and a reduction of DOX resistance in Caco-2 and CEM/ADR5000 cells (Eid et al., 2013). As an N-acylpiperidine, piperine inhibited the efflux of the tested substrate which led to an increase of its concentration in Caco-2 and CEM/ADR5000 cells (Li et al., 2018a). Tests of piperine on MCF-7/DOX and A-549/DDP cells resulted in an increase in cytotoxicity of MTX and DOX (Li et al., 2011). Gravacridonetriol, gravacridonediol and its monomethyl ether, all had an inhibitive effect on P-gp L5178/MDR1 cells, which also led to a higher cytotoxicity of DOX (Rethy et al., 2008). Substitution of methyl groups at the positions C-2 and C-4 of acridone led to the increased lipophilicity, which can enhance the binding affinity of acridone derivatives to P-gp (Mayur, 2015). Murahari et al. (2017) studied on 2,4-dimethylacridone derivatives and showed that these compounds were potential modulators of P-gp-mediated MDR. 2,4-dimethylacridones are tricyclic and hydrophobic and have methyl groups at C-2 and C-4 positions with a propyl or butyl side chain containing terminally substituted tertiary amino groups. They found that an alkyl side chain and hydroxyl substituted secondary amine are necessary for the acridones to reverse the P-gp-mediated multidrug resistance. Moreover, an alkyl side chain of length four (butyl) was found to have higher biological activity (Murahari et al., 2017). Hegde et al. (2004) reported that replacing the hydrogen atom at position C-4 by a methoxy group slightly enhanced the lipophilicity of the acridone derivatives. Furthermore, they investigated the MDR-reversing activity of N-10-substituted acridones and N-10-substituted 4-methoxyacridones relative to their corresponding unsubstituted counterparts where the C-4 positions of the acridone rings are occupied by a hydrogen atom and a methoxy group, respectively. The parent acridone and 4-methoxyacridone had the least effect in inhibiting drug efflux suggesting that N-10-substitution is necessary for an ideal activity. It was also found that 4-methoxyacridone derivatives are more efficient than their acridone derivatives' counterparts in increasing drug accumulation. Several N-10-substituted acridones and N-10-substituted-4-methoxyacridones showed MDR-reversing activity greater than the P-gp inhibitor verapamil (Hegde et al., 2004). In another study eighteen N-10-substituted-2-bromoacridones were examined for the anti-MDR activity and compared to the parent compound 2-bromo-10H-acridin-9-one. N-10-substitution was suggested to be necessary for optimal activity of 2-bromoacridones because the parent compound had the least effect in efflux inhibiting activity (Mayur et al., 2006).

Table 1

The effects of secondary metabolites on different cell lines expressing ABC-transporters – Transporters targeted directly
SubstanceCell lineAssay systemResultReference
Alkaloids
Quinolines, Isoquinolines, QuinazolinesDauriporphineMES-SA/DX5 and HCT15MDR reversing activity (cytotoxicity assay in the presence and absence of an anticancer drug, PTX)Increase in cytotoxicity of PTX (inhibition of P-gp MDR)Min et al. (2006)
FangchinolineMDR1-MDCK IIMDR reversing activityDecrease in substrate (PTX) efflux, inhibition of the multidrug resistance of antitumor drug PTXHe et al. (2010)
GlaucineCaco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopyReversal of DOX resistance in both cell lines with very high effect, synergism with DOXEid et al. (2013)
Caco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopySensitization of cell lines, enhancement of cytotoxicity, strong reduction of the IC50 value of DOX and consequently increase of efficacy, synergism with DOX and DTNEid et al. (2013)
MCF-7/ADRMDR reversing activity, ADR and MTX efflux assay, real-time RT-PCR, P-gp and MRP1 ATPase activity assayInhibition of P-gp and MRP1-mediated efflux, suppression of the expression of MDR1 and MRP1 genes, reversion of the resistance of MCF-7/ADR to ADR and MTX, increase in P-gp and MRP1 ATPase activitiesLei et al. (2013)
HernandezineMDR19-HEK293,
KB-V-1,
NCI-ADR-RES
MDR reversing activity, fluorescent drug (calcein-AM and pheophorbide A) accumulation assay,Inhibition of the transport function of ABCB1 (P-gp), increase in calcein-AM accumulation in MDR19-HEK293 cells, resensitizing of MDR19-HEK293 cells to DOX, resensitizing of KB-V-1 cells to DOX, colchicine and VCR, resensitizing of NCI-ADR-RES cells to DOX, colchicine and vincristineHsiao et al. (2016)
RoemerineMDR KB-V1Cytotoxicity assay with VBLCytotoxicity synergismYou et al. (1995)
SanguinarineCaco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopyReversal of DOX resistance in both cell lines with very high effect, synergism with DOXEid et al. (2013)
Caco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopySensitization of cell lines to DOXEid et al. (2013)
TetrandrineCaco-2, CEM/ADR5000Rh-123 accumulationIncreased accumulation of substrate, inhibited efflux in both cell lines, reduction of P-gp expressionSun and Wink (2014)
Quinidine homodimerMCF-7/DX1Radioactive substrate ([3H]PTX) accumulation assay, flow cytometric accumulation assay, confocal microscopyInhibition of the efflux of Rh-123, DOX, BODIPY-FL-prazosin, PTX and MTX,Pires et al. (2009)
Steroidal alkaloidsVerabenzoamineL5178/MDR1 (human MDR1-gene-transfected mouse lymphoma cells)Flow cytometric assay of Rh-123 accumulationIncrease in accumulationIvanova et al. (2011)
VeralosineL5178/MDR1Flow cytometric assay of Rh-123 accumulationIncrease in accumulationIvanova et al. (2011)
Veralosinine + VeranigrineL5178/MDR1Flow cytometric assay of Rh-123 accumulationIncrease in accumulationIvanova et al. (2011)
Indoles and β-carbolinesAntofineA549-PA (PTX-resistant human lung cancer cell line)P-gp expression using western blot, MDR-1 mRNA expression using RT-PCR, Rh-123 accumulation by FACSReduction of P-gp and MDR-1 mRNA expression, increase in intracellular Rh-123 content, synergism with PTXKim et al. (2012)
ArboloscineKB/VJ300MDR reversing activityModerate to weak activity in reversing MDRGan et al. (2014)
ConoduramineKB-V1Binding assay (VBL binding to KB-V1 vesicles)Inhibition of drug-binding, resulting in circumventing multi-drug resistanceYou et al. (1994)
CoronaridineKB-V1Binding assay (VBL binding to KB-V1 vesicles)Inhibition of drug-binding resulting in circumventing multi-drug resistanceYou et al. (1994)
HarmineMDA-MB-231 (BCRP), CEM/ADR5000 (P-gp)Rh-123 accumulation assay, cytotoxicity assay using MTT, MTX efflux assayReversal of MTX and CPT resistance in cell line with BCRP-mediated efflux, no effect on P-gp mediated effluxMa and Wink (2010)
Caco-2, CEM/ADR5000MTT assayReversal of DOX resistance in both cell lines, synergism with DOXEid et al. (2013)
Caco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopySensitization of cell lines to DOXEid et al. (2013)
KopsamineKB/VJ300MDR reversing activityAppreciable activity in reversing MDRKam et al. (1998)
KopsiflorineKB/VJ300MDR reversing activityAppreciable activity in reversing MDRKam et al. (1998)
Lahadinine AKB/VJ300MDR reversing activityAppreciable activity in reversing MDRKam et al. (1998)
Leuconicine (types A - E)KB/VJ300MDR reversing activityReversal of multidrug resistanceGan et al. (2009)
11-MethoxykopsilongineKB/VJ300MDR reversing activityAppreciable activity in reversing MDRKam et al. (1998)
N-methoxycarbonyl-11,12-methylene-dioxykopsinineKB/VJ300MDR reversing activityAppreciable activity in reversing MDRKam et al. (1998)
PleiocarpineKB/VJ300MDR reversing activityAppreciable activity in reversing MDRKam et al. (1998)
ReserpineCEM/VLB100MDR reversing activityIncrease in cytotoxicity, synergism with VBLPearce et al. (1989)
TryptanthrinCaco-2Transport across the Caco-2 cell monolayers, MDR1 & 2 gene expressionDecrease in the efflux transport of the P-gp and MRP2 substrates (potential inhibitor of P-gp and MRP2)Zhu et al. (2011)
VocamineKB-V1Binding assay (VBL binding to KB-V1 vesicles)Inhibition of drug-binding resulting in circumventing multi-drug resistanceYou et al. (1994)
YohimbineCEM/VLB100MDR reversing activityIncrease in cytotoxicity synergism with VBLPearce et al. (1989)
Piperidines, Pyrazines, Diketopiperazines11E-didehydrostemofoline, 11Z-didehydrostemofolineK562/AdrMTT assay; fluorescent substrates accumulation assaysIncrease in sensitivity to DOX and PTX; increase in the intracellular concentrations of Rh-123 and calcein-AMUmsumarng et al. (2017)
IsostemofolineK562/AdrMTT assay; fluorescent substrates accumulation assaysIncrease in sensitivity to DOX and PTX; increase in the intracellular concentrations of Rh-123 and calcein-AMUmsumarng et al. (2017)
LobelineCaco-2, CEM/ADR5000Rh-123 accumulation assay, cytotoxicity assay using MTT, MTX efflux assayInhibition of P-gp mediated efflux, accumulation of Rh-123, increase of DOX sensitivity of both cell linesMa and Wink (2008)
OxystemokerrineKB-V1MDR reversing activitySlight increase in sensitivityChanmahasathien et al. (2011)
PiperineMCF-7/DOX, A-549/DDPMDR reversing activity, Rh-123 accumulation assay, MTX efflux assay, RT-PCRReversal of resistance, decrease in ABCB1 and ABCG2 genes expression in MCF-7/DOX cells, decrease in ABCC1 gene expression in A-549/DDP cellsLi et al. (2011)
Caco-2, CEM/ADR 5000Cytotoxicity assay using MTT, Rh-123 and calcein-AM retention assaySubstrate, synergistic enhancement of cytotoxicity, inhibition of efflux and consequently accumulation of Rh-123 and calcein-AMLi et al. (2018a)
StemocurtisineKB-V1MDR reversing activitySlight increase of sensitivityChanmahasathien et al. (2011)
StemofolineKB-V1MDR reversing activityIncrease in cell sensitivityChanmahasathien et al. (2011)
TetramethylpyrazineMCF-7/DoxFlow cytometric evaluation of DOX accumulation, P-gp expressionInhibition of efflux, decrease in P-gp expressionZhang et al. (2012)
Tropane alkaloidsPervilleine AMDR KB-V1Intracellular VBL accumulation, cytotoxicityCytotoxicity synergism with VBL, increase in VBL accumulationMi et al. (2001)
Pervilleine B, CMDR KB-V1Cytotoxicity assayCytotoxicity synergism with VBLMi et al. (2002)
Acridone alkaloidsAcrimarine EK562/R7DNR accumulation assayInhibition of P-gp-mediated drug effluxBayet et al. (2007)
GravacridonediolL5178/MDR1Rh-123 accumulation assay, MTT assay, MDR1 mRNA expressionIncrease in Rh-123 accumulation, increase in DOX toxicity (synergism)Rethy et al. (2008)
Gravacridonediol monomethyl etherL5178/MDR1Rh-123 accumulation assay, MTT assay, MDR1 mRNA expressionIncrease in Rh-123 accumulation, cytotoxicity, synergism with DOX, decrease in MDR1 mRNARethy et al. (2008)
GravacridonetriolL5178/MDR1Rh-123 accumulation assay, MTT assay, MDR1 mRNA expressionIncrease in Rh-123 accumulation, cytotoxicity, synergism with DOX, decrease in MDR1 mRNARethy et al. (2008)
2-Methoxycitpressine IK562/R7DNR accumulation assayInhibition of p-glycoprotein-mediated drug effluxBayet et al. (2007)
RutacridoneL5178/MDR1Rh-123 accumulation assay, MTT assay, MDR1 mRNA expressionIncrease in Rh-123 accumulationRethy et al. (2008)
Purine alkaloidsOlomoucine IIMDCKII-ABCB1, HCT-8 and HepG2Hoechst 33342 and DNR accumulation assaySynergism with DNR (increase in intracellular retention of DNR)Cihalova et al. (2013}
Purvalanol AMDCKII-ABCB1, HCT-8 and HepG2Hoechst 33342 and DNR accumulation assaySynergism with DNR (increase in intracellular retention of DNR)Cihalova et al. (2013)
RoscovitineMDCKII-ABCB1, HCT-8 and HepG2Hoechst 33342 and DNR accumulation assaySynergism with DNR (increase in intracellular retention of DNR)Cihalova et al. (2013)
Further alkaloidsAnandamineHK-2Fluorimetric measurement of the intracellular accumulation of calceinInhibition efflux (increase in the intracellular accumulation of calcein)Nieri et al. (2006)
CapsaicinKB-C2Determination of DNR and Rh-123 accumulationIncrease in the accumulation of DNR and Rh-123Nabekura et al. (2005)
Caco-2[3H]-digoxin transport assayAt non-cytotoxic concentrations, inhibition of P-gp mediated efflux transport of [3H]-digoxinHan et al. (2006)
Caco-2, CEM/ADR 5000Cytotoxicity assay using MTT, Rh-123 and calcein-AM retention assaySubstrate, synergistic enhancement of cytotoxicity, inhibition of efflux and consequently accumulation of Rh-123 and calcein-AMLi et al. (2018a)
Galantamine dimerMCF-7/DX1Measuring Rh-123 and DOX accumulationInhibition of efflux (increased accumulation)Namanja et al. (2009)
Polyphenols
FlavonoidsAcacetinK562/BCRPCytotoxicity assayIncrease in cytotoxicity of SN-38 and MTX, strong reversing activity of BCRP-mediated drug resistancesImai et al. (2004)
MDA-MB-231BCECF accumulation assayInhibition of the efflux of MRP1 fluorescent substrate (BCECF) from breast cancer cellsWesołowska et al. (2009)
AfrormosinL5178/MDR1Cytotoxicity assay, Rh-123 accumulation assayModerately effective on the human MDR1-transfected mouse lymphoma cell lineGyémánt et al. (2005)
MDA-MB-231Cytotoxicity assay, BCECF-AM accumulation assayMRP-mediated efflux pump modifiers, additive effect in combination with epirubicinGyémánt et al. (2005)
AmorphigeninL5178/MDR1Cytotoxicity assay, Rh-123 accumulation assayP-gp-mediated efflux pump modifier (strong MDR-reversal effects), strong antiproliferative effects, synergistic effects in combination with epirubicinGyémánt et al. (2005)
ApigeninMCF-7 MX100MTX accumulation, cytotoxicity assayIncreasing accumulation and inhibition of BCRP in combination with other flavonoids e.g. biochanin A, and chrysinZhang et al. (2004)
K562/BCRPCytotoxicity assayStrong reversing activity of BCRP-mediated drug resistancesImai et al. (2004)
AmpelopsinK562/ADRMTT assay, P-gp expression assay using PE-labeled antibody, ADR accumulation assayDecreasing P-gp expression, reversal of MDR to ADR, increase in cytotoxicity and the intracellular ADR accumulationYe et al. (2009)
7,8-BenzoflavonMCF-7 MX100Topotecan accumulation studiesInhibition of the efflux, increasing the accumulation of topotecanZhang et al. (2005)
MCF-7/ADRDaunomycin accumulation assayDecrease of daunomycin efflux, increase in [3H]-daunomycin accumulation, strongly potentiated cytotoxicity of daunomycinChung et al. (2005)
Biochanin AMDA435/LCC6,
MCF-7/ADR, MDA435/LCCMDR1
Daunomycin accumulation, DOX cytotoxicityIncrease in [3H]-daunomycin accumulation, potentiation of DOX cytotoxicity, inhibition of P-gp-mediated cellular effluxZhang and Morris (2003)
Panc-1Determination of daunomycin and VBL accumulationIncrease in accumulation of daunomycin and VBL in Panc-1 cells, inhibiting MRP1-mediated drug transportNguyen et al. (2003)
MCF-7 MX100MTX accumulation, cytotoxicity assayIncreasing accumulation and inhibiting BCRP in combination with other flavonoids e.g. apigenin or chrysinZhang et al. (2004)
Caco-2Ochratoxin A (OTA) accumulation assayIncrease in OTA accumulation, impairing OTA efflux through competitive inhibition of MRP-2 pumpSergent et al. (2005)
CatechinRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayInhibitory effect on P-gp ATPase activityNajar et al. (2010)
NIH-3T3-G185Intracellular retention of Rh-123 or LDS-751 (P-gp marker substrate)Slight facilitation of the efflux of LDS-751 (providing a chemoprotective role)Wang et al. (2002)
ChalconePanc-1Determination of daunomycin and VBL accumulationIncreasing the accumulation of daunomycin and VBL in Panc-1 cells, inhibiting MRP1-mediated drug transportNguyen et al. (2003)
ChrysinCaCo-2Ochratoxin A (OTA) accumulation assayIncrease in OTA accumulation, impairing OTA efflux through competitive inhibition of MRP-2 pumpSergent et al. (2005)
MCF-7 MX100MTX accumulation, topotecan accumulation studies, cytotoxicity assayIncreasing accumulation and inhibiting BCRP in combination with other flavonoids e.g. Biochanin A, increase in accumulation of topotecan (inhibition of the BCRP-mediated transport of topotecan)Zhang et al. (2004; 2005)
K562/BCRPCytotoxicity assayStrong reversing activity of BCRP-mediated drug resistancesImai et al. (2004)
L5178/MDR1Cytotoxicity assay, Rh-123 accumulation assayP-gp-mediated efflux pump modifiers (increase in Rh-123 accumulation), strong antiproliferative effects, synergistic effects in combination with epirubicinGyémánt et al. (2005)
Chrysosplenol DStaphylococcus aureusS. aureus growth inhibition assaySynergism with berberine and norfloxacin
(Potentiated the activity of berberine and norfloxacin against a resistant strain of S. aureus), MDR pump inhibitor
Stermitz et al. (2002)
DiosmetinK562/BCRPCytotoxicity assayStrong reversing activity of BCRP-mediated drug resistancesImai et al. (2004)
DiosminCaco-2Accumulation of Rh-123Increase in accumulation of Rh-123Yoo et al. (2007a)
(+)EpicatechinNIH-3T3-G185Intracellular retention of Rh-123 or LDS-751 (P-gp marker substrate)Slightly facilitated active transport (efflux) of LDS-751 (providing a chemoprotective role)Wang et al. (2002)
(-)EpicatechinNIH-3T3-G185Intracellular retention of Rh-123 or LDS-751 (P-gp marker substrate)Significant enhance of the active transport (efflux) of LDS-751 (providing a chemoprotective role)Wang et al. (2002)
KB-C2Rh-123 and DNR accumulationNo effect on P-gp effluxKitagawa et al. (2004)
(-)Epicatechin gallateNIH-3T3-G185Intracellular retention of Rh-123 or LDS-751 (P-gp marker substrate)Slight inhibition of LDS effluxWang et al. (2002)
Epicatechin gallateKB-C2Rh-123 and DNR accumulationIncrease in cellular accumulation of Rh-123 and DNRKitagawa et al. (2004)
Bel-7404/DOX, mouse modelsCell proliferation, Rh-123 and DOX (DOX) accumulation assay,
semi-quantitative RT-PCR analysis of MDR1 mRNA expression
At higher doses a slight inhibitory effect on cell proliferation, administration of DOX with ECG at lower doses significant inhibition of cell proliferation in vitro and hepatoma growth in a xenograft mouse model, increase in DOX and Rh-123 accumulations, decreasing P-gp in cells concurrently treated by DOX and ECG, reduction of the expression of MDR1 mRNA in BEL-7404/DOX cells treated by DOX and ECGLiang et al. (2010)
(-)EpigallocatechinNIH-3T3-G185Intracellular retention of Rh-123 or LDS-751 (P-gp marker substrate)Inhibition of LDS effluxWang et al. (2002)
EpigallocatechinKB-C2Rh-123 and DNR accumulationIncreasing the accumulation of DNRKitagawa et al. (2004)
MDA-MB-231BCECF-AM accumulation assayMRP-mediated efflux pump modifiersGyémánt et al. (2005)
Epigallocatechin gallateNIH-3T3-G185Intracellular retention of Rh-123 or LDS-751 (P-gp marker substrate)Slight inhibition of the efflux of Rh-123, enhancing the efflux of LDSWang et al. (2002)
KB-C2Rh-123 and DNR accumulationIncrease in Rh-123 and DNR accumulation, decrease in the efflux of Rh-123Kitagawa et al. (2004)
Bel-7404/DOX, mouse modelsCell proliferation, Rh-123 and DOX (DOX) accumulation assay,
Semi-quantitative RT-PCR analysis of MDR1 mRNA expression
Slight inhibitory effect on cell proliferation at higher doses, significant inhibition of cell proliferation and hepatoma growth by the administration of DOX with EGCG at lower doses in vitro in a xenograft mouse model, increasing DOX and Rh-123 accumulations, decrease of P-gp in cells concurrently treated by DOX and EGCG, expression of MDR1 mRNA in BEL-7404/DOX cells treated by DOX and EGCG reducedLiang et al. (2010)
CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopyReversal of DOX resistance in the cancer cell lineEid et al. (2013)
Caco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopySensitization of cell lines to DOXEid et al. (2013)
MCF-7Cytotoxicity using MTS assay, P-gp protein expression using western blot and immunofluorescence microscopy, Rh-123 accumulationIncrease in intracellular Rh-123 accumulation, decrease in P-gp protein expression, reduction of cell viabilityReyes-Esparza et al. (2015)
Caco-2, CEM/ADR5000Cytotoxicity determination using MTT assay after combining with DOX, Rh-123 assay and Calcein-AM assay testing P-gp activityDOX sensitization, synergistic effect on the leukemia cell lineLi et al. (2018b)
Caco-2, CEM/ADR5000Cytotoxicity determination using MTT assay after combining with DOX + DTN, Rh-123 assay and Calcein-AM assay testing P-gp activityDOX sensitization, synergism in both cell linesLi et al. (2018b)
FormononetinL5178/MDR1Cytotoxicity assay, Rh-123 accumulation assayP-gp-mediated efflux pump modifier (strong MDR-reversal effects)Gyémánt et al. (2005)
MDA-MB-231Cytotoxicity assay, BCECF-AM accumulation assayMRP-mediated efflux pump modifier, synergistic effects in combination with epirubicinGyémánt et al. (2005)
GenisteinK562/BCRPTopotecan and [3H]Genistein accumulation, cytotoxicity assayIncreasing cytotoxicity of SN-38 and MTX, increasing accumulation of [3H]Genistein and topotecan, inhibition of BCRP-mediated drug effluxImai et al. (2004)
Panc-1Determination of daunomycin and VBL accumulationIncreasing the accumulation of DNM and VBL in Panc-1 cells, inhibiting MRP1-mediated drug transportNguyen et al. (2003)
CaCo2Ochratoxin A (OTA) accumulation assayIncrease in OTA accumulation, impairing OTA efflux through competitive inhibition of MRP-2 pumpSergent et al. (2005)
GlabridinMDCKIITransport of [3H]digoxinInhibition of P-gp-mediated transport of digoxinCao et al. (2007)
KB-C2DNR accumulationIncrease of DNR accumulation (inhibition of the P-gp-mediated efflux of DNR)Nabekura et al. (2008a)
3,3',4',5,6,7,8-HeptamethoxyflavoneK562/ADMUptake of [3H]vincristineIncreasing the uptake of [3H]vincristine (inhibition of P-gp mediated efflux of [3H]vincristine)Ikegawa et al. (2000)
KaempferolPanc-1Determination of daunomycin and VBL accumulationIncrease in accumulation of DNM and VBL in Panc-1 cells, inhibiting MRP1-mediated drug transportNguyen et al. (2003)
KB-C2Rh-123 and DNR accumulationIncrease in the accumulation of Rh-123 and DNR (inhibition of substrate efflux)Kitagawa et al. (2005)
K562/BCRPCytotoxicity assayIncreasing cytotoxicity of SN-38 and MTX, strong reversing activity of BCRP-mediated drug resistancesImai et al. (2004)
MDA-MB-231Cytotoxicity assay, BCECF-AM accumulation assayMRP-mediated efflux pump modifier, synergistic effects in combination with epirubicinGyémánt et al. (2005)
LuteolinK562/BCRPCytotoxicity assayStrong reversing activity of BCRP-mediated drug resistancesImai et al. (2004)
MorinMDA435/LCC6, MCF-7/ADR, MDA435/LCCMDR1Daunomycin (DNM) accumulation, P-gp ATPase activity assay, [3H]azidopine photoaffinity labelingIncrease in DNM accumulation, inhibition of P-gp ATPase activity, inhibition of P-gp-mediated cellular efflux, inhibition of [3H]azidopine photoaffinity labeling of P-gp suggesting a direct interaction with P-gp substrate bindingZhang and Morris (2003)
Panc-1Determination of daunomycin and VBL accumulationIncreasing the accumulation of DNM and VBL in Panc-1 cells, inhibiting MRP1-mediated drug transportNguyen et al. (2003)
MyricetinMDCKII-MRP1, MDCKII-MRP2Efflux of calcein (inhibition of MRP1 and MRP2 activity was studied
using the fluorescent calcein as a model substrate
Inhibition of MRP1 and MRP2 activity (inhibition of calcein efflux)van Zanden et al. (2005)
NaringeninMCF-7/ADR[3H]-Daunomycin (DNM) accumulation, [3H]-Daunomycin efflux studyIncrease in accumulation of DNM, decrease in efflux of DNMChung et al. (2005)
Caco-2The flux of talinolol across Caco-2 cell monolayersReduction of P-gp mediated secretory transport of talinolol (inhibition of P-gp)De Castro et al. (2008)
K562/BCRPCytotoxicity assay, topotecan accumulationIncrease in cytotoxicity of SN-38 and MTX, increase in accumulation of topotecanImai et al. (2004)
Naringenin-7-glucosidK562/BCRPCytotoxicity assayInhibition of BCRP-mediated drug resistanceImai et al. (2004)
NobiletinKB-C2, KB/MRPAccumulation assay of DNR in KB-C2 cells and calcein in KB/MRP cells, P-gp ATPase activityIncrease in the accumulation of DNR in KB-C2 cells, increase in calcein accumulation in KB/MRP cells, stimulation of ATPase activity of P-gpNabekura et al. (2008b)
K562/ADMUptake of [3H]vincristineIncrease in the uptake of [3H]vincristine (inhibition of P-gp mediated efflux of [3H]vincristine)Ikegawa et al. (2000)
A2780/T, A549/TCytotoxicity assay (SRB assay); intracellular accumulation of Rh-123, DOX and Flutax-2 using flow cytometrySensitization of cells to chemotherapeutic drugs PTX, DOX, DNR and docetaxel; synergism with PTX; increase in intracellular accumulation of Rh-123, DOX and Flutax-2Ma et al. (2015)
PhloretinMDA435/LCC6, MCF-7/ADRDaunomycin (DNM) accumulationIncrease in DNM accumulation, inhibition of P-gp-mediated cellular effluxZhang and Morris (2003)
Panc-1Determination of daunomycin and VBL accumulationIncrease in the accumulation of DNM and VBL in Panc-1 cells, inhibiting MRP1-mediated drug transportNguyen et al. (2003)
Mouse lymphoma/MDR1 cellsRh-123 accumulationModerate inhibition of effluxMolnár et al., 2010 (review)
ProcyanidineRat brain microvessel endothelial cells (RBMECs)Rh-123 intracellular accumulation assay, Rh-123 efflux assay, P-gp ATPase activity measurementIncrease in the accumulation of Rh-123, decrease in Rh-123 efflux, inhibition of the P-gp ATPase activityHe et al. (2009)
QuercetinPanc-1Determination of daunomycin and VBL accumulationIncrease in the accumulation of DNM and VBL in Panc-1 cells, inhibition of MRP1-mediated drug transportNguyen et al. (2003)
CaCo2Ochratoxin A (OTA) accumulation assayIncrease of OTA accumulation, impairing OTA efflux through competitive inhibition of MRP-2 pumpSergent et al. (2005)
BEL/5-FUCytotoxicity assay; Rh-123 and ADR accumulation using flow cytometry; ABCB1, ABCC1, ABCC2 mRNA and protein expression using real-time PCR and western blotIncrease in sensitivity to chemotherapeutic drugs 5-FU, MMC and ADR; increase in intracellular Rh-123 and ADR accumulation; decrease in ABCB1, ABCC1 and ABCC2 mRNAs and proteins expressionChen et al. (2018)
RobinetinMDCKII-MRP1, MDCKII-MRP2Efflux of calcein (inhibition of MRP1 and MRP2 activity was studied
using the fluorescent calcein as a model substrate
Inhibition of MRP1 and MRP2 activity (inhibited calcein efflux)van Zanden et al. (2005)
RobininMDA-MB-231Cytotoxicity assay, BCECF-AM accumulation assayMRP-mediated efflux pump modifiers, additive effects in combination with epirubicinGyémánt et al. (2005)
RotenoneMouse lymphoma/MDR1,
COLO320/MDR1
Rh-123 accumulationInhibited efflux, increased Rh-123 accumulationMolnár et al., 2010 (review)
L5178/MDR1Cytotoxicity assay, Rh-123 accumulation assayP-gp-mediated efflux pump modifier (MDR modulating activity), strong antiproliferative effects, additive effects in combination with epirubicinGyémánt et al. (2005)
SilymarinMCF-7/ADR[3H]-Daunomycin (DNM) accumulation, [3H]-Daunomycin efflux studyIncrease in the accumulation of DNM, decrease in efflux of DNMChung et al. (2005)
MDA435/LCC6, MCF-7/ADR, MDA435/LCCMDR1Daunomycin (DNM) accumulation, P-gp ATPase activity assay, [3H]azidopine photoaffinity labelingIncrease in DNM accumulation, inhibition of P-gp ATPase activity, inhibition of P-gp-mediated cellular efflux, inhibition of [3H]azidopine photoaffinity labeling of P-gp suggesting a direct interaction with the P-gp substrate bindingZhang and Morris (2003)
Panc-1Determination of daunomycin and VBL accumulationIncrease in the accumulation of DNM and VBL in Panc-1 cells, inhibition of MRP1-mediated drug transportNguyen et al. (2003)
TangeretinK562/ADMUptake of [3H]vincristineIncrease in the uptake of [3H]vincristine (inhibition of P-gp mediated efflux of [3H]vincristine)Ikegawa et al. (2000)
StilbenoidsResveratrolKB-C2Determination of DNR and Rh-123 accumulationIncrease in the accumulation of DNR, decrease in the efflux of Rh-123Nabekura et al. (2005)
CaCo2Ochratoxin A (OTA) accumulation assayIncrease of OTA accumulation, impairing OTA efflux through competitive inhibition of MRP-2 pumpSergent et al. (2005)
Caco-2, CEM/ADR5000Cytotoxicity assay using MTT, Rh-123 accumulation assayIncrease in Rh-123 accumulation, enhancement of DOX cytotoxicityEl-Readi et al. (2019)
CurcuminoidsCurcuminSGC7901/VCRAnalysis of apoptosis by propidium iodide (PI)-stained flow cytometry (FCM) and a morphological assay using acridine orange (AO)/ethidium bromide (EB) dual staining, accumulation and efflux of Rh123 as measured by flow
cytometry, expression of P-gp by FCM using fluorescein isothiocyanate (FITC)-conjugated anti-P-gp
Promotion of VCR-mediated apoptosis, increase in Rh-123 accumulation and inhibition of the efflux of Rh-123, downregulation of P-gp expressionTang et al. (2005)
KBV20CVCR, PTXIncreasing cytotoxicityUm et al. (2008)
KB-C2Determination of DNR and Rh-123 accumulationIncrease in the accumulation of DNR and Rh-123Nabekura et al. (2005)
Caco-2, LLC-PK1, LLC-GA5-COL300DNR transport (apical to basolateral (a-b) and basolateral to apical (b-a)) across Caco-2 cell monolayers, calcein-AM uptake in LLC-PK1 and LLC-GA5-COL300 cellsDecrease in the efflux ratio of DNR, increase of calcein-AM accumulation in LLC-GA5-COL300Ampasavate et al. (2010)
Caco-2, CEM/ADR5000Cytotoxicity determination using MTT assay after combining with DOX, Rh-123 assay and Calcein-AM assay testing P-gp activityDOX sensitization, synergistic effect on the colon cancer cell lineLi et al. (2018b)
Caco-2, CEM/ADR5000Cytotoxicity determination using MTT assay after combining with DOX + DTN, Rh-123 assay and Calcein-AM assay testing P-gp activityDOX sensitization, synergism in both cell linesLi et al. (2018b)
BisdemethoxycurcuminCaco-2, LLC-PK1, LLC-GA5-COL300DNR transport (apical to basolateral (a-b) and basolateral to apical (b-a)) across Caco-2 cell monolayers, calcein-AM uptake in LLC-PK1 and LLC-GA5-COL300 cellsDecrease in the efflux ratio of DNRAmpasavate et al. (2010)
Demethoxycurcumin,Caco-2, LLC-PK1, LLC-GA5-COL300DNR transport (apical to basolateral (a-b) and basolateral to apical (b-a)) across Caco-2 cell monolayers, calcein-AM uptake in LLC-PK1 and LLC-GA5-COL300 cellsDecrease in the efflux ratio of DNR, increase of calcein-AM accumulation in LLC-GA5-COL300Ampasavate et al. (2010)
TetrahydrocurcuminKB-V1, MCF-7 MDRRh-123 and calcein-AM accumulation assay by FACS in KB-V1 cells, radiolabeled drug ([3H]-VBL) accumulation for MCF-7 MDRIncrease in the accumulation of Rh-123 and calcein-AM in KB-V-1 cells, increase in the accumulation and inhibition of the [3H]-VBL efflux in MCF-7 MDRLimtrakul et al. (2007)
OthersTannic acidCaco-2, CEM/ADR5000Cytotoxicity determination using MTT assay after combining with DOX, Rh-123 assay and Calcein-AM assay testing P-gp activityDOX sensitization, synergistic effect on the colon cancer cell lineLi et al. (2018b)
Caco-2, CEM/ADR5000Cytotoxicity determination using MTT assay after combining with DOX + DTN, Rh-123 assay and Calcein-AM assay testing P-gp activityDOX sensitization, synergism in both cell linesLi et al. (2018b)
Phenylpropanoids
Neo-/lignansArctigeninCaco-2Cytotoxicity determination using MTT assay after combining with DOX, Rh-123 accumulation assay testing P-gp activitySynergism in Caco-2 cells and slight synergistic effect in CEM/ADR5000, increase in Rh-123 accumulationSu et al. (2015)
Caco-2, CEM/ADR5000Cytotoxicity determination using MTT assay after combining with DOX + DTN, Rh-123 accumulation assay testing P-gp activitySignificant increase in synergism of combination with DOX by DTN, increase in Rh-123 accumulationSu et al. (2015)
ArctiinCaco-2, CEM/ADR 5000Cytotoxicity determination using MTT assay after combining with DOX, Rh-123 accumulation assay testing P-gp activityModerate synergistic effect in CEM/ADR (concentration-dependent) and in Caco-2 cells, increase in Rh-123 accumulationSu et al. (2015)
Cytotoxicity determination using MTT assay after combining with DOX + DTN, Rh-123 accumulation assay testing P-gp activitySignificant increase in synergism of combination with DOX by DTN, increase in Rh-123 accumulationSu et al. (2015)
Epimagnolin AFlp-In-293/ABCB1MTT assay; calcein assayEnhancement of sensitivity to anti-cancer drugs DNR, DOX, VBL and VCR; inhibition of calcein effluxMitani et al. (2018)
Iso-/lappaol ACaco-2Cytotoxicity determination using MTT assay after combining with DOX, Rh-123 accumulation assay testing P-gp activitySlight synergistic effect in Caco-2 cells, additive effect in CEM/ADR cells, increase in Rh-123 accumulationSu et al. (2015)
Caco-2, CEM/ADR5000Cytotoxicity determination using MTT assay after combining with DOX + DTN, Rh-123 accumulation assay testing P-gp activitySignificant increase in synergism of combination with DOX by DTN, increase in Rh-123 accumulationSu et al. (2015)
Lappaol CCaco-2, CEM/ADR 5000Cytotoxicity determination using MTT assay after combining with DOX, Rh-123 accumulation assay testing P-gp activitySynergistic effect in CEM/ADR (concentration-dependent) and in Caco-2 cellsSu et al. (2015)
Caco-2, CEM/ADR 5000Cytotoxicity determination using MTT assay after combining with DOX + DTN, Rh-123 accumulation assay testing P-gp activitySignificant increase in synergism of combination with DOX by DTNSu et al. (2015)
Lappaol FCaco-2, CEM/ADR 5000Cytotoxicity determination using MTT assay after combining with DOX, Rh-123 accumulation assay testing P-gp activityModerate synergism in CEM/ADR 5000 cells with concentration-dependent activity, stronger effect in Caco-2 cells, increase in Rh-123 accumulationSu et al. (2015)
Cytotoxicity determination using MTT assay after combining with DOX + DTN, Rh-123 accumulation assay testing P-gp activitySignificant increase in synergism of combination with DOX by DTN, increase in Rh-123 accumulationSu et al. (2015)
MatairesinolKB-C2, KB/MRPDNR and calcein accumulation assayIncreasing accumulation of DNR (inhibits the P-gp-mediated efflux of DNR) and calcein (inhibits the MRP1-mediated efflux of calcein)Nabekura et al. (2008a)
Caco-2, CEM/ADR 5000Cytotoxicity determination using MTT assay after combining with DOX, Rh-123 accumulation assay testing P-gp activitySynergistic effect in Caco-2 cells, increase in Rh-123 accumulation, reversal of multidrug resistanceSu et al. (2015)
Caco-2, CEM/ADR 5000Cytotoxicity determination using MTT assay after combining with DOX + DTN, Rh-123 accumulation assay testing P-gp activitySignificant increase in synergism of combination with DOX by DTN, increase in Rh-123 accumulation
SesaminKB-C2DNR accumulation assayIncrease in DNR accumulation (inhibition of the P-gp-mediated efflux of DNR)Nabekura et al. (2008a)
Dibenzocyclo-octadienelignansGomisin AHepG2-DRCellular Rh-123 accumulation assay by flow cytometry, determination of P-gp-associated ATPase activity, photoaffinity labeling of P-gp with [125I]iodoarylazidoprazosinRestoration of the cytotoxicity of VBL and DOX, inhibition of the P-gp ATPase activity, additive effect with verapamil and vanadate on the inhibition of Rh-123 efflux, inhibition of [125I]IAAP photo-crosslinking of P-gpWan et al. (2006)
Schisandrin A (Deoxyschizandrin)Caco-2Rh-123 uptake assay, bidirectional transports of digoxin and Rh-123Increase in Rh-123 accumulation, increase in apical-to-basal transports of digoxin and Rh-123, decrease in basal-to-apical transportsYoo et al. (2007b)
COR-L23/RMTT assay, DOX accumulation assayRestoration of the cytotoxic action of DOX to COR-L23/R cells, increase in the accumulation of DOXSlaninová et al. (2009)
Schisandrin B/γ-SchizandrinCOR-L23/RMTT assay, DOX accumulation assayRestoration of the cytotoxic action of DOX to COR-L23/R cells, increase in the accumulation of DOXSlaninová et al. (2009)
Schisandrol AHepG2-DRFlow cytometry analyses of cell cycle and Rh-123 efflux, P-gp-ATPase activity assayStrong synergistic effect (enhanced cytotoxicity) with DOX, VBL and taxol, restoration VBL-induced G2/M arrest, increase in cellular retention of Rh-123, stimulation of basal P-gp-ATPaseFong et al. (2007)
OthersChlorogenic acidRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayInhibitory effect on P-gp ATPase activityNajar et al. (2010)
Ginkgolic acidKB-C2DNR accumulationIncrease of DNR accumulation (inhibiting the P-gp-mediated efflux of DNR)Nabekura et al. (2008a)
Terpenes
MonoterpenesCitronellalLLC-GA5-COL150Intracellular accumulation of [3H]digoxinIncrease in [3H]digoxin accumulationYoshida et al. (2005)
(R)-(+)-citronellalLLC-GA5-COL150Intracellular accumulation of [3H]digoxinIncrease in [3H]digoxin accumulationYoshida et al. (2005)
(S)-(–) β-citronellolLLC-GA5-COL150Intracellular accumulation of [3H]digoxinIncrease in [3H]digoxin accumulationYoshida et al. (2005)
CineoleLLC-GA5-COL150Intracellular accumulation of [3H]digoxinIncrease in [3H]digoxin accumulationYoshida et al. (2005)
DL-citronellolLLC-GA5-COL150Intracellular accumulation of [3H]digoxinIncrease in [3H]digoxin accumulationYoshida et al. (2005)
MentholCaco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopyReversal of DOX resistance in both cell lines, synergism with DOXEid et al. (2013)
Caco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopySynergism with DOXEid et al. (2013)
ThymolCaco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopySynergism with DOXEid et al. (2013)
Caco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopySynergism with DOXEid et al. (2013)
Iridoid glucosidesAgnusideRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayInhibitory effect on P-gp ATPase activityNajar et al. (2010)
NegundosideRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayStimulatory effect on P-gp ATPase activityNajar et al. (2010)
Picroside-IRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayStimulatory effect on P-gp ATPase activityNajar et al. (2010)
Picroside-IIRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayInhibitory effect on P-gp ATPase activityNajar et al. (2010)
SesquiterpenesAromadendreneCaco-2, CEM/ADR5000MTT assay using, Rh-123 accumulation assay using fluorospectroscopySynergism with DOXEid et al. (2013)
Caco-2, CEM/ADR5000MTT assay using, Rh-123 accumulation assay using fluorospectroscopySynergism with DOXEid et al. (2013)
Farnesiferol BMCF-7/AdrCytotoxicity using alamar blue assay, accumulation of Rh-123 using flow cytometryIncrease in cytotoxicity of DOX, increase in intracellular accumulation of Rh-123Kasaian et al. (2015)
Farnesiferol CMCF-7/AdrCytotoxicity using alamar blue assay, accumulation of Rh-123 using flow cytometryIncrease in cytotoxicity of DOX, increase in intracellular accumulation of Rh-123Kasaian et al. (2015)
LehmferinMCF-7/AdrCytotoxicity using alamar blue assay, accumulation of Rh-123 using flow cytometryIncrease in cytotoxicity of DOX, increase in intracellular accumulation of Rh-123Kasaian et al. (2015)
SantoninRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayInhibitory effect on P-gp ATPase activityNajar et al. (2010)
UmbellipreninMCF-7/AdrCytotoxicity using alamar blue assay, accumulation of Rh-123 using flow cytometryIncrease in cytotoxicity of DOX, increase in intracellular accumulation of Rh-123Kasaian et al. (2015)
DiterpenesAndrographolideRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayBiphasic effect (stimulation at low concentration and inhibition at high concentration)Najar et al. (2010)
Carnosic acidKB-C2, KB/MRPAccumulation assay of DNR and Rh-123 in KB-C2 and calcein in KB/MRP cells, ATPase activity assay, resistance to VBL cytotoxicity by a calorimetric assayIncrease in the accumulation of DNR and Rh-123 in KB-C2 cells, stimulation of the P-gp ATPase activity, sensitization of KB-C2 cells to VBL cytotoxicityNabekura et al. (2010)
CarnosolKB-C2, KB/MRPAccumulation assay of DNR and Rh-123 in KB-C2 and calcein in KB/MRP cells, ATPase activity assay, resistance to VBL cytotoxicity by a calorimetric assayIncrease in the accumulation of DNR and Rh-123 in KB-C2 cells, stimulation of P-gp ATPase activityNabekura et al. (2010)
Esulatin ML5178Y‐MDRMTT assay; Rh-123 accumulation assaySynergistic interaction with DOX; increase in intracellular accumulation of Rh-123Reis et al. (2016)
EpoxywelwitscheneL5178Y‐MDRMTT assay; Rh-123 accumulation assaySynergistic interaction with DOX; increase in intracellular accumulation of Rh-123Reis et al. (2016)
Euphoboetirane A, C, D, E, F, G and IL5178Y‐MDRMTT assay; Rh‐123 accumulation assayIncrease in intracellular Rh-123 accumulation; synergism with DOXNeto et al. (2019)
EuphotuckeyanolL5178/MDR1Rh-123 accumulation assay, in vitro antiproliferative effect in combination with epirubicin using checkerboard microplate methodInhibition of Rh-123 efflux (increase in accumulation), exhibition of a synergistic interaction with epirubicin and enhancement of the antiproliferative effect of epirubicinDuarte et al. (2008)
Euphowelwitschine A, BL5178Y‐MDRMTT assay; Rh-123 accumulation assaySynergistic interaction with DOX; increase in intracellular accumulation of Rh-123Reis et al. (2016)
12‐Hydroxyboetirane A, B and CL5178Y‐MDRMTT assay; Rh‐123 accumulation assayIncrease in intracellular Rh-123 accumulation; synergism with DOXNeto et al. (2019)
Latilagascene A, B, CL5178/MDR1Assay for Rh-123 accumulationInhibition of Rh-123 efflux (increase in accumulation)Duarte et al. (2006)
Latilagascene G, H, IL5178/MDR1Rh-123 accumulation assay, in vitro antiproliferative effect in combination with epirubicin using checkerboard microplate methodInhibition of Rh-123 efflux (increase in accumulation), exhibition of a synergistic interaction by all compounds with epirubicin and enhancement of the antiproliferative effect of epirubicinDuarte et al. (2008)
TotarolStaphylococcus aureus SA-K3092 (Totarol-resistant mutant overexpressing norA)Checkerboard combination studies using ethidium bromide (EtBr) and totarol, EtBr efflux assay, modulatory activity of totarol at half the MICReduction of the MICs of selected antibiotics by subinhibitory concentrations (suggesting that it may be an efflux pump inhibitor), reduction of ethidium efflux and ethidium MIC in SA-K3092Smith et al. (2007)
Tuckeyanol A, BL5178/MDR1Rh-123 accumulation assay, in vitro antiproliferative effect in combination with epirubicin using checkerboard microplate methodInhibition of Rh-123 efflux (increase in accumulation), exhibition of a synergistic interaction by both compounds with epirubicin and enhancement of the antiproliferative effect of epirubicinDuarte et al. (2008)
WelwitscheneL5178Y‐MDRMTT assay; Rh-123 accumulation assayIncrease in intracellular accumulation of Rh-123Reis et al. (2016)
Triterpenoids, Saponins*β-AmyrinMDR1-transfected mouse lymphoma cellsAccumulation of Rh-123, accumulation of ethidium bromide (semi-automated ethidium bromide fluorometric method)Increase in the accumulation of ethidium bromide (inhibitory activity against the P-gp transporter)Martins et al. (2010)
Cumingianol A, B, DKB-C2Cytotoxicity assay (MTT)Enhancement of cytotoxicity against KB-C2 cells in the presence of colchicineKurimoto et al. (2011a)
Cumingianol DMCF7Cytotoxicity assay (MTT)Moderate cytotoxicityKurimoto et al. (2011a)
DeacetylnomilinCEM/ADR5000, Caco-2Measurement of DOX cytotoxicity (reversal assay), Rh-123 efflux assayInhibition of Rh-123 efflux in CEM/ADR5000 cells, increase in DOX cytotoxicity in Caco-2 cellsEl-Readi et al. (2010)
Dyscusin AKB-C2Cytotoxicity assay (MTT)Enhancement of cytotoxicity against KB-C2 cells in the presence of colchicineKurimoto et al. (2011b)
Glycyrrhetinic acid (Enoxolone)KB-C2, KB/MRPDNR and calcein accumulationIncreasing DNR (inhibits the P-gp-mediated efflux of DNR) and calcein (inhibits the MRP1-mediated efflux of calcein) accumulationNabekura et al. (2008a)
Glycyrrhizin*Rats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayBiphasic effect (stimulation at low concentration and inhibition at high concentration)Najar et al. (2010)
LimoninCEM/ADR5000, Caco-2Measurement of DOX cytotoxicity (reversal assay), Rh-123 efflux assayInhibition of Rh-123 efflux in CEM/ADR5000 cells, enhancement of DOX cytotoxicity in CEM/ADR5000 and Caco-2 cellsEl-Readi et al. (2010)
ObacunoneMES-SA/DX5, HCT15Cytotoxicity assay in the presence of PTXSignificant inhibition of the P-gp MDR activityMin et al. (2007)
Oleanolic acidRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayStimulatory effect on P-gp ATPase activityNajar et al. (2010)
MDR1-transfected mouse lymphoma cellsAccumulation of Rh-123, accumulation of ethidium bromide (semi-automated ethidium bromide fluorometric method)Increase in the accumulation of ethidium bromide (inhibitory activity against the P-gp transporter)Martins et al. (2010)
Sinocalycanchinensin EKB-C2Cytotoxicity assay (MTT)Enhancement of the cytotoxicity against KB-C2 cells in the presence of colchicineKashiwada et al. (2011)
Ursolic AcidKB-C2, KB/MRPAccumulation assay of DNR and Rh-123 in KB-C2 and calcein in KB/MRP cells, ATPase activity assay, resistance to VBL cytotoxicity by a calorimetric assayIncrease in the accumulation of DNR and Rh-123 in KB-C2 cells, stimulation of P-gp ATPase activityNabekura et al. (2010)
UvaolMDR1-transfected mouse lymphoma cellsAccumulation of Rh-123, accumulation of ethidium bromide (semi-automated ethidium bromide fluorometric method), checker-board assay (for the study of synergism between uvaol and DOX)Increase in the accumulation of Rh-123 and ethidium bromide (inhibitory activity against the P-gp transporter), synergism with DOX cytotoxicityMartins et al. (2010)
Steroids, Saponins*Alisol B 23-acetateHepG2-DR, K562-DRCellular Rh-123 and DOX accumulation, photoaffinity labeling of P-gp with [125I]iodoarylazidoprazosin, P-gp ATPase activity,Enhancement of VBL toxicity, restoration of the activity of VBL in causing G2/M arrest, increase in DOX accumulation, delay of Rh-123 efflux, inhibition of the photoaffinity labeling of P-gp by [125I]IAAP, stimulation of the P-gp ATPase activityWang et al. (2004)
11α-O-benzoyl-12β-O-acetyltenacigenin BHepG2/DOXMDR reversing potential evaluation (comparing IC50 values of an anticancer drug in the absence or presence of 11-Alpha-O-benzoyl-12β-O-acetyl-tenacigenin B)Increase in the sensitivity of HepG2/Dox cells to the antitumor drugs DOX, VBL, puromycin, and PTXHu et al. (2008)
DTNCaco-2, CEM/ADR5000MTT assay using, Rh-123 accumulation assay using fluorospectroscopyReversal of DOX resistance, reduction of the IC50 value of DOXEid et al. (2013)
Ginsenoside M1, M4 and M12 (hydrolyzed metabolites of ginsenoside)KB-C2DNR accumulation, verapamil-induced ATPase activity (for M4)Increase in DNR accumulation by M1, M4 and M12; decrease of ATPase activity by M4 (most potent substance in this study)Kitagawa et al. (2007)
Ginsenoside Rc and RdMultidrug resistant mouse lymphoma cellsModerate reduction of the activity of the efflux pumpBerek et al. (2001)
Ginsenoside Rg3*KBV20CRh-123 retention assay, photo-affinity labeling with [3H]azidopine, [3H]VBL accumulation, cytotoxicity assay using Sulforhodamine B cell staining methodIncrease in accumulation of Rh-123, inhibition of [3H]VBL efflux, prevention of binding of [3H]azidopine to P-gp, restoration of the sensitivity of KBV20C cells to DOX, COL, VCR, and VP-16Kim et al. (2003)
Ginsenosides Rg1, Rc, Rd, Re*Multidrug resistant mouse lymphoma cellsModerate inhibitory effect on the drug efflux pumpMolnár et al. (2000)
GuggulsteroneKB-C2, KB/MRPAccumulation assay of DNR and Rh-123 in KB-C2 cells and calcein in KB/MRP cells, ATPase activity of P-gp and MRP1Increase in Rh-123 and DNR accumulation in KB-C2 cells, inhibition of Rh-123 efflux from KB-C2 cells, increase in the accumulation of calcein in KB/MRP cells, stimulation of ATPase activities of P-gp and MRP1Nabekura et al. (2008c)
Methylprototribestin*L5178/MDR1Rh-123 accumulation, checkerboard microplate method to study the interaction (MDR reversal effect) between the methylprototribestin and DOXIncrease in Rh-123 accumulation, synergistic interaction between methylprototribestin and DOXIvanova et al. (2009)
Protopanaxatriol ginsenosides*AML-2/D100Accumulation assay of DNR, [3H]-azidopine photolabeling of P-gpReversing the resistance to DNR, increase in DNR accumulation, inhibition of [3H]-azidopine photolabeling of P-gpChoi et al. (2003)
β-sitosterol-O-glucoside*CEM/ADR5000, Caco-2Measurement of DOX cytotoxicity (reversal assay), Rh-123 efflux assayInhibition of Rh-123 efflux in CEM/ADR5000 cells, increase in the cytotoxicity of DOX in Caco-2 cellsEl-Readi et al. (2010)
Caco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopyReversal of DOX resistance in both cell lines, synergismEid et al. (2013)
Caco-2, CEM/ADR5000MTT assay, Rh-123 accumulation assay using fluorospectroscopySensitization of cell lines, enhancement of cytotoxicity, light reduction of the IC50 value of DOX, synergism in the Caco-2 cellsEid et al. (2013)
StigmasterolCaco-2, CEM/ADR5000Measurement of DOX cytotoxicity (reversal assay), Rh-123 efflux assayInhibition of Rh-123 efflux in CEM/ADR5000 cells, increase in the cytotoxicity of DOX in Caco-2 cellsEl-Readi et al. (2010)
Tenacigenin B: P8, P26 and P27SW620/Ad300 (P-gp-overexpressing)
MCF-7/VP (MRP-1-overexpressing)
MCF-7/FLV1000 (ABCG2-overexpressing)
MDR reversal effect on cytotoxicity of anticancer drugs DOX (substrate of P-gp and MRP1) and MTX (substrate of ABCG2), flow cytometry-based efflux assay of Rh-123 (P-gp substrate), calcein AM (MRP1 substrate) and PhA (ABCG2 substrate)Effective in circumventing MDR mediated by P-gp, MRP1 and ABCG2, inhibition of P-gp efflux activity, increase in intracellular concentration of the substrate drugs through the inhibition of MRP1- and ABCG2-mediated effluxTo et al. (2017)
Tenacigenin B: P2, P3 and P6SW620/Ad300 (P-gp-overexpressing),
MCF-7/VP (MRP-1-overexpressing),
MCF-7/FLV1000 (ABCG2-overexpressing)
MDR reversal effect on cytotoxicity of anticancer drugs DOX (substrate of P-gp and MRP1) and MTX (substrate of ABCG2), flow cytometry-based efflux assay of Rh-123 (P-gp substrate), calcein AM (MRP1 substrate) and PhA (ABCG2 substrate)Effective in circumventing MDR mediated by P-gp and MRP1, inhibition of P-gp efflux activity by P2 and P6, increase in the intracellular concentration of the substrate drug via inhibition of MRP1-mediated effluxTo et al. (2017)
Tenacigenin B: P1, P4, P5, P9 and P28SW620/Ad300 (P-gp-overexpressing)
MCF-7/VP (MRP-1-overexpressing)
MCF-7/FLV1000 (ABCG2-overexpressing)
MDR reversal effect on cytotoxicity of anticancer drugs DOX (substrate of P-gp and MRP1) and MTX (substrate of ABCG2), flow cytometry-based efflux assay of Rh-123 (P-gp substrate), calcein AM (MRP1 substrate) and PhA (ABCG2 substrate)Effective in circumventing P-gp-mediated MDR, P1 and P5 inhibition of P-gp efflux activityTo et al. (2017)
Tenacissimoside A*HepG2/DOXDOX accumulation, Rh-123 and Hoechst 33342 efflux assay, cell cycle analysis, MDR reversing potential evaluation (comparing IC50 values of an anticancer drug in the absence or presence of Tenacissimoside A)Increase in the sensitivity of HepG2/Dox cells to the antitumor drugs DOX, VBL, puromycin, and PTX, increase in DOX accumulation, enhancement of the action of DOX in causing G2/M arrest, inhibition of the efflux of Rh-123 and Hoechst 33342Hu et al. (2008)
TetraterpenesAurochromeL5178/MDR1Rh-123 accumulation assayModerate inhibition of P-gpGyémánt et al. (2006)
CanthaxanthinCaco-2, CEM/ADR5000MTT assay, activity determination using Rh-123- and Calcein-AM retention assaySignificant enhancement of cytotoxicity and synergism using the following drugs: PTX, Cycloheximide, DOX, VBL,
amphotericin-B, 5-FU, etoposide and cisplatine
Eid et al. (2012)
CapsanthinMDR1 gene-transfected mouse lymphoma (L1210) cellsRh-123 accumulation assayInhibition of the efflux, very active in MDR reversal effectMolnár et al. (2006)
CapsorubinHuman MDR1-gene-transfected mouse lymphoma (L1210) cellsRh-123 accumulation assayMDR reversal activity, enhancement of Rh-123 accumulationMolnár et al. (2006)
β-caroteneCaco-2, CEM/ADR5000MTT assay, activity determination using Rh-123- and Calcein-AM retention assaySynergism, significant enhancement of cytotoxicity of DOX, VBL,
amphotericin-B, 5-FU, etoposide and cisplatine; substrate
Eid et al. (2012)
Caco-2, CEM/ADR5000MTT assay using, Rh-123 accumulation assay using fluorospectroscopySensitization of cell lines, enhancement of cytotoxicity, strong reduction of the IC50 value of DOX and consequently increase of efficacy, synergismEid et al. (2013)
Caco-2, CEM/ADR5000MTT assay using, Rh-123 accumulation assay using fluorospectroscopyReversal of DOX resistance in both cell lines, synergismEid et al. (2013)
ABCB1/Flp-InTM-293MTT assay; calcein-AM accumulation assayIncrease in cytotoxicity of DOX; increase in intracellular concentration of calceinTeng et al. (2016)
CrocinCaco-2, CEM/ADR5000MTT assay, activity determination using Rh-123- and Calcein-AM retention assaySynergism, enhancement of cytotoxicity of DOX, VBL, cisplatine; substrateEid et al. (2012)
DiepoxycaroteneL5178/MDR1Rh-123 accumulation assayModerate inhibition of P-gpGyémánt et al. (2006)
FucoxanthinCaco-2, CEM/ADR5000MTT assay, activity determination using Rh-123- and Calcein-AM retention assaySignificant enhancement of cytotoxicity and synergism using the following drugs: PTX, Cycloheximide, DOX, VBL,
amphotericin-B, 5-FU, etoposide and cisplatine
Eid et al. (2012)
MutatochromeL5178/MDR1Rh-123 accumulation assayModerate inhibition of P-gpGyémánt et al. (2006)
Retinoic acidCaco-2, CEM/ADR5000MTT assay, activity determination using Rh-123- and Calcein-AM retention assaySignificant enhancement of cytotoxicity and synergism using the following drugs: DOX, VBL, 5-FU, etoposide and cisplatineEid et al. (2012)
Benzopyrones
Coumarins/coumaric acidsAurapteneKB-C2 and KB/MRPAccumulation assay of DNR in KB-C2 cells and calcein in KB/MRP cells, P-gp ATPase activityIncrease in the accumulation of DNR in KB-C2 cells, stimulation of the P-gp ATPase activityNabekura et al. (2008b)
HT29Cytotoxicity assay (MTT), real-time RT-PCRSynergic effects with cisplatin, DOX and VCR, increase in the toxicity of applied radiations in auraptene pretreated cells, overexpression of p21 in auraptene pretreated cells after radiotherapyMoussavi et al. (2017)
BergamottinK562/ADM[3H]vincristine uptakeIncrease in [3H]vincristine uptake, weak MDR reversal activityIkegawa et al. (2000)
ClausarinK562/R7DNR accumulation assayInhibition of P-gp-mediated drug effluxBayet et al. (2007)
Dicynnamoyl-cis-khellactoneHepG2/Dox, K562/DoxDOX accumulation and efflux assay, MDR reversing activity (cytotoxicity assay in the presence and absence of an anticancer drug), cell cycle distributionIncrease in DOX uptake and reduction of DOX efflux in HepG2/Dox cells, increase in cytotoxicity of anticancer drugs VBL, DOX, puromycin and PTX in HepG2/Dox and K562/Dox cells, enhancement of DOX-induced G2/M arrest in HepG2/Dox cellsShen et al. (2006)
DihydroxybergamottinK562/ADM[3H]vincristine uptakeIncrease in [3H]vincristine uptake, weak MDR reversal activityIkegawa et al. (2000)
PhyllodulcinKB-C2DNR accumulationIncrease in DNR accumulation (inhibition of P-gp-mediated efflux of DNR)Nabekura et al. (2008a)
Praeruptorin AHepG2/Dox, K562/DoxMDR reversing activity (cytotoxicity assay in the presence and absence of an anticancer drug)Increase in cytotoxicity of anticancer drugs VBL, DOX, puromycin and PTX in HepG2/Dox and K562/Dox cellsShen et al. (2006)
Others
DibenzopyranMagniferinRats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayBiphasic effect (stimulation at low concentration and inhibition at high concentration)Najar et al. (2010)
Phenols[6]-GingerolKB-C2Determination of DNR and Rh-123 accumulationIncrease in accumulation of DNR and Rh-123Nabekura et al. (2005)
GlucosideParishin CLymphoma cellsModerate reduction of the activity of the efflux pumpBerek et al. (2001)
Phenyl propanoidActeoside (Verbascosine)Rats jejunal membrane in vitroP-gp stimulation/inhibition profiles using a P-gp-dependent ATPase assayInhibitory effect on P-gp ATPase activityNajar et al. (2010)

Phytochemicals modulating MDR via ABC-transporters.

*Saponins are marked with asterisks.

Research on olomoucine, purvalanol and roscovitine revealed amongst other things the inhibitive potential of purine alkaloids on P-gp in the form of MDCKII-ABCB1 cells and human HCT-8 and HepG2 cells while olomoucine had the strongest effect of all (Cihalova et al., 2013). Several groups have run experiments with the benzazepine alkaloid capsaicin on different cell lines such as KB-C2, Caco-2 and CEM/ADR5000. The most relevant result was the inhibition of P-gp efflux in the presence of digoxin as substrate at non-toxic concentrations (Nabekura et al., 2005; Han et al., 2006; Li et al., 2018a).

Isoflavonoids and some flavonoids often act as phytoestrogens. Investigations revealed that hydroxyl groups at position C-5 and C-7 are an important property for the P-gp inhibitory effect of flavonoids, although hydrophobicity usually promotes the affinity (Sheu et al., 2010). Acacetin, genistein, kaempferol and naringenin, were examined by Imai et al. (2004) and it resulted in positive effects on K562 cells expressing BCRP. The cytotoxicity of MTX and 7-ethyl-10-hydroxycamptothecin was enhanced using phytoestrogens. In addition, genistein and naringenin enhanced the accumulation of topotecan in K562/BCRP cells. Also apigenin had strong reversal effect on BCRP-mediated MDR (Imai et al., 2004). In MCF-7 MX100 cells, which also overexpressed BCRP, apigenin had similar effect on the accumulation of the anticancer agent MTX (Zhang et al., 2004). However, naringenin, which differs from apigenin only in the saturation of C-2 and C-3, had a significant loss of potency in comparison to the latter due to the lack of a double bond (Conseil et al., 1998). Several groups experimented with the isoflavone and phytoestrogen biochanin A and its outcome on BCRP and P-gp in cell lines such as Panc-1, MCF-7 MX100, MDA435/LCC6, MCF-7/ADR, MDA435/LCCMDR1 and Caco-2. In all studies, an inhibition of drug efflux, an increase of accumulation and a potentiation of cytotoxicity were observed. A combination of biochanin A with some other flavonoids yielded additive effects (Nguyen et al., 2003; Zhang and Morris, 2003; Zhang et al., 2004; Sergent et al., 2005). Nobiletin and tangeretin prevented the P-gp mediated efflux of [3H]vincristine (Ikegawa et al., 2000). Among other flavones with methoxyls they were examined by Ohtani et al. (2007) for the uptake potential of [3H]vincristine as a P-gp substrate. The MDR-reversing effect increased with the number of methoxyl moieties but with the exception of both at C-3′ and C-5′ position on B-ring. In this case there was even a decrease of MDR-reversing potency. Chrysin is a hydroxyflavone with simple structure which has also been examined by a number of groups. The competitive inhibition of the MRP-2 pumps in Caco-2 cells and an antiproliferative effect of chrysin are certain (Gyémánt et al., 2005; Sergent et al., 2005). Moreover, a prevention of BCRP and P-gp mediated efflux took place in MCF-7 MX100 cells and L5178 cells, respectively (Zhang et al., 2004; Zhang et al., 2005; Gyémánt et al., 2005). A prenyl or geranyl group at C-6 and C-8 of chrysin, and a prenyl in both positions ensured an improvement of the binding affinity to P-gp. In addition, there was more potency for inhibition after geranylation than prenylation which could be due to its level of lipophilicity (Di Pietro et al., 2002). In contrast, glycosylation taking place at any position tested, dramatically decreased the binding affinity of flavonoids (Sheu et al., 2010). Another way to gain binding affinity toward the C-terminal nucleotide-binding domain of P-gp, were other kinds of alkylation of chrysin including methyl, benzyl, isopropyl and 3,3-dimethylallyl (Boumendjel et al., 2002).

Several experiments have been carried out for the flavan epigallocatechin gallate (EGCG), a derivative of epigallocatechin (EGC) abundant in green tea. EGCG has been tested on different cells such as liver cancer cells Bel-7404/DOX, the colon cancer cell line Caco-2, leukemia cells CEM/ADR5000, endocervical adenocarcinoma cells KB-C2 and others. An increase of drug accumulation and sensitization in these and several other cell lines was observed (Kitagawa et al., 2004; Liang et al., 2010; Eid et al., 2013; Reyes-Esparza et al., 2015). Particularly substitutions at D-ring had positive effect on EGC and derivatives. A derivative of EGC with three methoxy groups in cis-configuration at D-ring and an oxycarbonylvinyl as its connection to C-3 led to a higher potency. This structure only regulated P-gp and could not affect BCRP or MRP1 (Wong et al., 2015).

While curcumin is a promising agent for liver protection and inhibition of cancerous cell growth, other curcuminoids like demethoxycurcumin and tetrahydrocurcumin have being studied more closely. They inhibited the efflux of chemptherapeutics and consequently increased cellular accumulation of drugs (Limtrakul et al., 2007; Ampasavate et al., 2010).

Among phenylpropanoids, some lignans (Figure 5) showed an inhibitory effect on P-gp. Schisandrin A was used on Caco-2 cells resulting in an increase in apical-to-basal transport and cytotoxicity Yoo et al. (2007b). A study which examined the structure activity of lignans showed the benefit of the absence of a hydroxyl group in position C-8 as in schisandrin A and γ-schizandrin for the function as p-gp inhibitor. In addition, a higher effect was seen in R-configurated biaryl than in the S-configuration (Slaninová et al., 2009). The reversal of cytotoxicity in CEM/ADR 5000 and Caco-2 cells was moreover successful by using menthol or thymol, monoterpenes obtained from volatile oils. They could reduce the IC50 value of doxorubicin which enhances the effectiveness of the drug (Eid et al., 2013).

Figure 5

Figure 5

Chemical structures of some selected lignans with MDR reversal effects.

Reis et al. (2016) reported that jatrophane diterpenes including esulatin M, epoxywelwitschene, welwitschene, and euphowelwitschine A were more efficative in MDR cells than the positive control verapamil. In comparison to the known MDR modifier verapamil, euphoboetirane C, D, E, F, and G extracted from Euphorbia boetica showed multifold P-gp modulatory activity in L5178Y‐MDR cells (Neto et al., 2019). Three types of latilagascenes (G, H and I), macrocyclic diterpene esters, were effective in L5178 cells expressing P-gp as transport inhibitors (Duarte et al., 2008). All successfully tested diterpenes mentioned above had a cyclopentane moiety in their structure. An enormous increase of activity was observed due to their saturation. Moreover, there was lower MDR-reversing activity mostly when the number of three hydroxyls was exceeded, especially in position 5, 7, 9 and 12. Nevertheless hydropxyls at C-1, C-13, C-14 and C-15 had not any negative effect on their function (Zhu et al., 2016). Vasas et al. (2011) observed that the lack of oxygenation at C-2 increased the MDR-reversing activity in diterpene jatrophanes such as 3β,5α,15β-triacetoxy-7β-isobutanoyloxyjatropha-6(17),11E-diene-9,14-dione and 3β,5α,15β-triacetoxy-7β-isobutanoyloxy-9α-nicotinoyloxyjatropha-6(17),11-dien-14-one. Furthermore, they stated that the presence of benzoyl or nicotinoyl group at C-2 instead of an acetyl group increases the potency of jatrophane diterpenes. The reversal of MDR was noticed in some triterpenoids including ursolic acid tested in KB-C2 cells (Nabekura et al., 2010), and deacteylnomilin and limonin in CEM/ADR5000 cells (El-Readi et al., 2010). A study on triterpenoids such as tormentic acid and derivatives suggests that an acetylation of C-2 of a terpenoid can cause an increase of activity, while this is not the case with the acetylation of C-3 (da Graça Rocha et al., 2007). Carotenoids, a group derived from tetraterpenes, are substrates for ABC transporters and can effectively modulate MDR in cancer cells (Eid et al., 2012). A few types such as β-carotene (Eid et al., 2013) or the xanthophyll member capsorubin showed MDR reversal activity (Molnár et al., 2006). To mention another important group with aromatic members, coumarins and coumaric acids are benzopyrones which we presented in Tables 1 and 2. Auraptene for example not only caused an enhancement of drug uptake (Nabekura et al., 2008b); its effect even was of a synergistic kind with drugs such as cisplatin and VCR (Moussavi et al., 2017). Kasaian et al. (2015) examined fifteen sesquiterpene coumarins. Considering the structure-activity relationship they described that ring-opened drimane-type sesquiterpene coumarins such as lehmferin, farnesiferol B and farnesiferol C showed the best P-gp inhibitory effects. Their study also revealed that farnesiferol C inhibited the Rh-123 efflux even more than the positive control verapamil.

Table 2

The effects of secondary metabolites on different cell lines expressing ABC-transporters – Regulation of the expression
SubstanceCell lineAssay systemResultReference
Alkaloids
Quinolines, Isoquinolines, QuinazolinesBerbamineK562/ADRP-gp expression using flow cytometry, mdr-1 gene expression using RT-PCRReduction of MDR1 gene expressionDong et al. (2004)
BerberineOC2 and KB (oral-), SC-M1 and NUGC-3 (gastric-), COLO 205 (colon cancer cell line)Pgp-170 protein expression using flow cytometryUpregulation of P-gp expression in tested cell lines, decrease in retention of Rh-123Lin et al. (1999a)
Hep3B, HepG2,
HA22T/VGH
Rh-123 retention and MDR1 transporter level using flow cytometryIncrease in MDR1 transporter level in HepG2, Hep3B, and HA22T/VGH cells, decrease in retention of Rh-123 in HepG2Lin et al. (1999b)
A10 (rat vascular smooth muscle cells)MDR1a and MDR1b gene expression by RT-PCRIncrease in expression of MDR1a and MDR1b mRNASuzuki et al. (2010)
3Y1, dRLh-84, B16Rh-123 retention using flow cytometry, MDR1a and MDR1b protein expression using western blotIncrease in MDR1a and MDR1b protein level, decrease in intracellular Rh-123 concentrationSuzuki et al. (2010)
CoptisineA10MDR1a and MDR1b gene expression by RT-PCR, MDR1a and MDR1b protein expression using western blot, Rh-123 retention using flow cytometryIncrease in MDR1a and MDR1b mRNA and protein level, decrease in intracellular Rh-123 contentSuzuki et al. (2010)
3Y1, dRLh-84, B16Rh-123 retention using flow cytometry, MDR1a and MDR1b protein expression using western blotIncrease in the level of MDR1a and MDR1b protein, decrease in intracellular Rh-123 concentrationSuzuki et al. (2010)
FangchinolineCaco-2, CEM/ADR5000MDR reversal assay (effect on DOX cytotoxicity), Rh-123 accumulation assay, western blot (P-gp expression level)Increase in intracellular Rh-123 accumulation, decrease in P-gp expression, synergism in combination with DOXSun and Wink (2014)
GlaucineMCF-7/ADRMDR reversing activity, ADR and MTX efflux assay, real-time RT-PCR, P-gp and MRP1 ATPase activity assayInhibition of P-gp and MRP1-mediated efflux, suppression of the expression of MDR1 and MRP1 genes, reversion of the resistance of MCF-7/ADR to ADR and MTX, increase in P-gp and MRP1 ATPase activitiesLei et al. (2013)
O-(4-ethoxyl-butyl)-berbamineMCF-7/ADRMCF-7/ADR sensitivity to ADR (MTT assay), Rh-123 retention using flow cytometry, expression of mdr-1gene using RT-PCRSensitization to ADR, increase in the accumulation of Rh-123, reduction of MDR1 gene expressionCheng et al. (2006)
PalmatineA10MDR1a and MDR1b gene expression by RT-PCRIncrease in the expression of MDR1a and MDR1b mRNASuzuki et al. (2010)
3Y1, dRLh-84, B16MDR1a and MDR1b protein expression using western blot, Rh-123 retention using flow cytometryIncrease in the level of MDR1a and MDR1b protein, increase in intracellular Rh-123 contentSuzuki et al. (2010)
TetrandrineCaco-2, CEM/ADR5000MDR reversal assay (effect on DOX cytotoxicity), Rh-123 accumulation assay, western blot (P-gp expression level)Increase in intracellular Rh-123 accumulation, decrease in P-gp expression, synergism in combination with DOXSun and Wink (2014)
K562 (DOX-treated vs. tetrandrine+DOX-treated group)mRNA expression using RT-PCR, detecting P-gp expression as well as Rh-123 accumulation by FACSDecrease in DOX-induced MDR1 mRNA expression, inhibition of DOX-induced P-gp expression, increase in Rh-123 accumulationShen et al. (2010)
Quinolizidine alkaloidsMatrineMCF-7/ADRWestern blot for labelling P-gp and MRP1 proteins, fluorospectrophotometry for ADR accumulation assayReduction of P-gp expression, increase in intracellular accumulation of ADR, decrease in cell growthZhou et al. (2017)
Indoles and β-carbolinesAntofineA549-PAP-gp expression using western blot, MDR-1 mRNA expression using RT-PCR, Rh-123 accumulation by FACSReduction of P-gp and MDR-1 mRNA expression, increase in intracellular Rh-123 content, synergism with PTXKim et al. (2012)
EphedrineK562/A02MDR1 gene expression using semi-quantitative RT-PCR, P-gp expression using western blotDecrease in MDR1 mRNA and P-gp expressionGao et al. (2008)
Indole-3-carbinolHepatocytes of mouse treated with combination of indole-3-carbinol and VBL/VCR (in vivo)P-gp expression using western blot, quantitative stereology using immunohistochemical staining with anti-P-gp antibodyInhibition of VBL/VCR-induced P-gp expressionArora and Shukla (2003)
StaurosporineMDR KB-V1Cytotoxicity, P-gp expression using western blot, MDR1 gene expression by northern blotCytotoxicity synergism with verapamil, sensitization of cells to VBL when co-treated with verapamil, decrease in P-gp and MDR1 gene expressionSampson et al. (1993)
VauquelineK562/A02MDR1 gene expression using semi-quantitative RT-PCR, P-gp expression using western blotDecrease in MDR1 mRNA and P-gp expressionGao et al. (2008)
Piperidines, Pyrazines, DiketopiperazinesPiperineMCF-7/DoxABCB1 and ABCG2 mRNA expression by semi-quantitative RT-PCR; fluorescent dye efflux assay, cytotoxicity assay (MTT)Decrease in ABCB1 and ABCG2 mRNA expression, increase in intracellular Rh-123 and MTX accumulation, reversal of resistance to DOX and MTXLi et al. (2011)
A-549/DDPABCC1 mRNA expression by semi-quantitative RT-PCR; fluorescent dye efflux assay, cytotoxicity assay (MTT)Decrease in ABCC1 mRNA expression, increase in intracellular DOX accumulation, reversal of resistance to DOX
TetramethylpyrazineMCF-7/DoxDOX retention by flow cytometry, P-gp expression using western blot, MDR1 expression using RT-PCRIncrease in DOX retention, reversal of resistance to PTX, VCR and DOX; decrease in P-gp and MDR1 mRNA expressionZhang et al. (2012)
Pumc-91/ADM,
T24/DDP
Cell viability assay using Cell Counting Kit-8, qRT-PCR for MRP1 mRNA, western blot and immunofluorescence assay for MRP1 protein expressionDecrease in MRP1 protein and mRNA expression, reversal of MDR (increase in cytotoxicity of ADR and DDP)Wang et al. (2016)
BEL-7402/ADMADR accumulation by flow cytometry and HPLC, gene expression using RT-PCR, protein expression by western blotDecrease in MDR1, MRP2, MRP3 and MRP5 mRNA and proteins expression, increase in ADR intracellular accumulation, increase in ADR cytotoxicity (MDR reversal effect)Wang et al. (2010)
Acridone alkaloidsGravacridonetriolL5178/MDR1Rh-123 retention, MTT antiproliferative assay, MDR1 expression by RT-PCRDecrease in Rh-123 efflux, increase in DOX cytotoxicity (synergism), decrease in MDR1 mRNA expressionRethy et al. (2008)
Gravacridonediol monomethyl etherL5178/MDR1Rh-123 retention, MTT antiproliferative assay, MDR1 expression by RT-PCRDecrease in Rh-123 efflux, increase in DOX cytotoxicity (synergism), decrease in MDR1 mRNA expressionRethy et al. (2008)
NucleosidesClitocineR-HepG2, MES-SA/Dx5DOX retention by flow cytometry, western blot for P-gp and qRT-PCR for MDR1 expressionDecrease in MDR1 mRNA and P-gp expression, reversal of MDR (enhancement of DOX cytotoxicity), increase in DOX accumulationSun et al. (2012)
SulfinosineNCI-H460/R, U87-TxRDOX retention by flow cytometry, western blot for P-gp and RT-PCR for MDR1 mRNA expressionDecrease in MDR1 mRNA and P-g expression, increase in DOX accumulation, decrease in resistance to DOX (enhancement of DOX cytotoxicity)Dačević et al. (2013)
Further alkaloidsCapsaicinCaco-2[3H]-digoxin retention, western blot for P-gp and RT-PCR for MDR1 mRNA expressionIncrease in P-gp and MDR1 mRNA expression, increase in [3H]-digoxin effluxHan et al. (2006)
HomoharringtonineCEM/E1000MTT assayDecrease in cell viability, modulation of MRP1-mediated MDREfferth et al. (2002)
Polyphenols
FlavonoidsAmpelopsinK562/ADRMTT assay, P-gp expression by PE-labeled antibody, ADR accumulation using flow cytometryDecrease in P-gp expression, increase in ADR cytotoxicity and intracellular accumulation, synergism with ADRYe et al. (2009)
BaicaleinLS174T, HepG2MTT assay, MDR1 expression using real-time PCRDecrease in cell viability, increase in MDR1 expression in LS174TLi et al. (2010)
EpicatechingallateBel-7404/DOXMTT assay, Rh-123 retention by flow cytometry, intracellular DOX content using fluorospectrophotometry, semi-quantitative RT-PCR, P-gp expression by FACS using anti-P-gp monoclonal antibodyIncrease in DOX and Rh-123 accumulation, and DOX cytotoxicity (synergism), decrease in MDR1 and P-gp expressionLiang et al. (2010)
Epigallocatechin gallateBel-7404/DOXMTT assay, Rh-123 retention by flow cytometry, intracellular DOX content using fluorospectrophotometry, semi-quantitative RT-PCR, P-gp expression by FACS using anti-P-gp monoclonal antibodyIncrease in DOX and Rh-123 accumulation, and DOX cytotoxicity (synergism),decrease in MDR1 and P-gp expressionLiang et al. 2010)
MCF-7TamMTT assay, RT-PCR, western blot for P-gp and BCRP protein expression, Rh-123 and MTX accumulationReduction of cell proliferation, decrease in P-gp and BCRP expression, increase in MTX accumulationFarabegoli et al. (2010)
MCF-7Cytotoxicity using MTS assay, P-gp protein expression using western blot and immunofluorescence microscopy, Rh-123 accumulationIncrease in Rh-123 accumulation, decrease in P-gp protein expression, reduction of cell viabilityReyes-Esparza et al. (2015)
QuercetinHL-60/ADM, K562/ADMMDR reversal by MTT assay, RT-PCR, flow cytometrySensitization to DNR, decrease in MRP1 gene and protein expressionCai et al. (2004; 2005)
BEL/5-FUCytotoxicity assay; Rh-123 and ADR accumulation using flow cytometry; ABCB1, ABCC1, ABCC2 mRNA and protein expression using real-time PCR and western blotIncrease in sensitivity to chemotherapeutic drugs 5-FU, MMC and ADR; increase in Rh-123 and ADR accumulation; decrease in ABCB1, ABCC1 and ABCC2 mRNAs and proteins expressionChen et al. (2018)
CurcuminoidsBisdemethoxycurcuminKB-V1RT-PCR, western blotDecrease in MDR1 and P-gp expressionLimtrakul et al. (2004)
CurcuminSKOV3(TR)Cytotoxicity in combination with PTX, western blotEnhancement of PTX cytotoxic activity, reduction of P-gp expressionGanta and Amiji (2009)
HCT-8/VCRMTT assay, Rh-123 retention, MDR1 and survivin genes expression by RT-PCRReversal of MDR, decrease in MDR1 expression, increase in substrate accumulationLu et al. (2013)
Neo-/lignansHonokiolMCF-7/ADRMTT assay, Rh-123 retention, qPCR, P-gp expression by FACSIncrease in Rh-123 retention, reduction of MDR1 and P-gp expression, increase in ADR cytotoxicityXu et al. (2006)
Dibenzocyclo-octadienelignansSchisandrin A
(Deoxyschizandrin)
KBV200, MCF-7/Dox, Bel7402MTT assay (cytotoxicity in combination with DOX, VCR and PTX), DOX and Rh-123 retention, RT-PCR, western blot for P-gp expressionIncrease in Dox and Rh-123 retention, reduction of MDR1 and P-gp expression, sensitization to cytotoxic drugsHuang et al. (2008)
COR-L23/RMTT assay, DOX retention by flow cytometryElevation of DOX cytotoxicity, increase in DOX accumulationSlaninová et al. (2009)
Schisandrin B/γ-SchizandrinCOR-L23/RMTT assay, DOX retention by flow cytometryElevation of DOX cytotoxicity, increase in DOX accumulationSlaninová et al. (2009)
Terpenoids
SesquiterpenesArtesunateCEM/E1000,
CEM/VLB100
MTT assay, DNR retention assay by flow cytometryDecrease in cell viability, increase in DNR accumulation, modulation of MDR1- and MRP1-mediated MDREfferth et al. (2002)
EGb761HepG2MDR1 expression by real-time RT-PCRInduction of MDR1 expressionLi et al. (2009)
DiterpenesGinkgolide A and BHepG2MDR1 expression by real-time RT-PCRInduction of MDR1 expressionLi et al. (2009)
TriptolideIn vitro (KB-7D, KB-tax)
In vivo (KB-7D-,KB-tax-bearing mouse)
In vitro growth inhibition assay, western blot for MDR1 and MRP1 protein expression, in vivo tumor weight evaluationInhibition of cell growth, decrease in MDR1 and MRP1 protein expression, inhibition of tumor growth, decrease in tumor weight when combined with 5-fluorouracil (synergism effect)Chen et al. (2010)
DU145/ADMMTT assay, RT-PCR, western blotIncrease in ADR cytotoxicity, reduction of MDR1 mRNA and protein expressionGuo et al. (2013)
Benzopyrones
Coumarins/coumaric acidsPyranocoumarinsKB-V1Sulforhodamine B cytotoxicity assay, DOX retention by flow cytometry, MDR1 mRNA Expression using RT-PCR, P-gp expression by western blotSynergism with DOX, VCR, puromycin and PTX; increase in intracellular accumulation of DOX; decrease in P-gp and MDR1 mRNA expressionWu et al. (2003)
Phenols
6-Gingerol, 10-GingerolPC3RCytotoxicity assay, MRP-1 protein expression using western blotReduction of cell survival, decrease in MRP-1 protein expressionLiu et al. (2017)
6-Shogaol, 10-ShogaolPC3RCytotoxicity assay, MRP-1 protein expression using western blotReduction of cell survival, decrease in MRP-1 protein expressionLiu et al. (2017)

Phytochemicals Modulating Transporter or Protein Expression.

The studies introduced phytochemicals with completely different basic structures, each showing both strong and ineffective members in targeting ABC-transporters. The molecules mentioned were a selection chosen due to their effectiveness, especially in relation to the substances to which they were compared.

Phytochemicals Modulating Transporter or Protein Expression

The following discussion focusses on the question how far phytochemicals affect the expression of ABC transporters or proteins in cancer cell lines. A list of relevant publications is documented in Table 2. Although many investigations addressed the inhibitory effect of secondary metabolites on transporter activity, many phytochemicals regulate the expression of corresponding genes, including alkaloids, polyphenols, lignans, terpenes and benzopyrones. Berbamine caused a downregulation of Mdr-1 expression in K562/ADR cells (Dong et al., 2004), and so did its derivative O-(4-ethoxylbutyl)-berbamine (Cheng et al., 2006). Glaucine not only functioned as inhibitor of transporters but also reduced the expression of MDR1 and MRP1 (Lei et al., 2013) while the isoquinoline alkaloids berberine and coptisine, mediated the expression of P-gp (Lin et al., 1999a). Tetramethylpyrazine downregulated the expression of MDR1, MRP2, MRP3 and MRP5 in BEL-7402/ADM cells (Wang et al., 2010). It has also reduced the expression of MDR1 and MRP1 in MCF-7/Dox and Pumc-91/ADM cells, respectively (Zhang et al., 2012; Wang et al., 2016). MDR1 mRNA and P-gp expression were reduced in response to clitocine and sulfinosine in several cell lines, such as R-HepG2, MES-SA/Dx5, NCI-H460/R and U87-TxR (Sun et al., 2012; Dačević et al., 2013). Among polyphenols, EGCG mediated a reduction of P-gp and BCRP expression resulting in drug accumulation (Farabegoli et al., 2010). Curcumin enhanced the cytotoxicity of PTX and ADR, respectively against SKOV3(TR) and K562/A02 cells by reducing the expression of P-gp in both cell lines (Chang et al., 2006; Ganta and Amiji, 2009). While some diterpenes and sesquiterpenes induced the transporter expression (Li et al., 2009), others like triptolide suppressed the expression of MDR1 and MRP1 proteins in KB-7D and KB-tax cells (Chen et al., 2010). Beside the positive effect of some coumarins on the activity of ABC transporters, pyranocoumarin was tested on KB-V1 cells and showed a reduction of P-gp protein and MDR1 expression (Wu et al., 2003).

Athough no clear relationship could be established between the structure of a modulator with thre expression of a transporter protein, these findings can be relevant for clinical applications.

Synergistic Combinations of Chemotherapeutics With Phytochemicals

In addition to affecting the activity or expression of transporters, phytochemicals can also reverse MDR in cancer cells through synergism. Phytochemicals causing synergistic interactions with anticancer drugs are documented in Tables 1 and 2. The two-drug combination of harmine with DOX not only showed an enhancement of cytotoxicity but a synergistic effect. Glaucine potentiated DOX toxicity in Caco-2 and CEM/ADR5000 cells and reversed their resistance to anticancer drugs. Glaucine exerted synergistic interaction with DOX and even more in a three drug combination with DTN (Eid et al., 2013). Euphoboetirane C, D, F, G, H and I extracted from Euphorbia boetica showed strong synergistic interactions with DOX in L5178Y‐MDR cells (Neto et al., 2019). Nobiletin and antofine showed synergistic interactions with PTX (Kim et al., 2012; Ma et al., 2015). Jatrophane diterpenes including euphowelwitschine A, euphowelwitschine B, epoxywelwitschene, esulatin M isolated from Euphorbia welwitschii demonstrated synergism with DOX in L5178Y‐MDR cells (Reis et al., 2016). Fangchinoline, tetrandrine, and pyranocoumarins has been shown to synergistically increase the cytotoxicity of DOX (Wu et al., 2003; Sun and Wink, 2014). These synergistic effects are probably caused by interference of the phytochemicals with ABC transporters and additional molecular targets in cancer cells (Wink et al., 2012). These studies show that a combination of substances can have a great advantage over using single drugs against cancer cells by exploiting synergism.

In Silico Analysis of Phytochemicals as MDR Reversing Agents

In Silico experiments are promising methods for making predictions about interactions of molecules to the drug-binding site of a target such as P-gp, BCRP and MRP1. Molecular docking studies can help finding the phytochemicals with best affinity for the drug-binding site which should be used as lead molecules for further studies. The nucleotide-binding domains (NBD) of these ABC-Transporters are hydrophilic protein parts (Jones and George, 2002). In addition to essential hydrogen bonds which play a crucial role in maintaining the stability and function of biomolecules, modulators with hydrophobic moieties often show affinties to NBDs.

The benzolisoquinoline alkaloid tetrandrine was confirmed to have inhibitory capability. Its binding affinity is close to verapamil and their docking positions are similar. Main part of tetrandrine is fixed in a lipophilic pocket formed by the amino acids Ala729, Ala987, Ileu306, Ileu340, Leu339, Leu65, Leu975, Met69, Met986, Phe303, Phe336, Phe343, Phe728, Phe732, Phe983, Tyr307, Tyr310. Moreover, the positively charged methylamine moiety of tetrandrine formed a cation-π interaction with Phe343 and an aryl ether got into a π-π interaction with Phe336 (Liao et al., 2019).

Regarding in silico investigations, another subtype of alkaloids, piperine was examined by Syed et al. (2017) revealing that hydrophobic interactions with P-gp took place in following positions: Leu339, Met69, Met986, Phe72, Phe336, Phe728, Phe983, Tyr953 and Val982. Moreover, an H-bond with Tyr307 was established. Two piperine analogs were designed which showed better hydrophobic interaction with most of the amino acids mentioned (Syed et al., 2017).

Pharmacophore modeling which was carried out for acridones indicated that three aromatic rings and two H–acceptors which are given in position C-9 bearing a carbonyl group and N-10 were conducive for stable docking. Including designed analogs of acridone the oxygen of a morpholine moiety at a phenyl ring built a water bridge with Ser309 of P-gp and a carboxamide at C-4 helped docking with Phe343. This analog showed hydrophobic interactions with Ala229, Ala302, Ala342, Ile218, Ile221, Ile299, Ile306, Leu225 with even more than two interactions, Leu339, Phe343, and Val345 of P-gp (Gade et al., 2018).

Badhan and Penny (2006) worked on the main characteristics of the pharmacophore of flavonoids by in silico modeling. Flavonoids tested get located within the C-terminal NBD of P-gp binding to amino acids of the ATP pocket such as Tyr1044. The hydroxyl moiety at C-5 of natural flavonoids can form a water bridge with Lys1076 while the hydroxyl group in position 3 and the carbonyl group get into hydrogen bonds within the NBD. Hydroxyl groups at position C-7 led to important hydrogen bonds with amino acids for several flavonoids such as EGC and chrysin (Wongrattanakamon et al., 2017). Ring B gets involved in π- π interaction with Tyr1044. If benzyl, geranyl or prenyl groups added at C-6 and several substitutes added at C-8 position, the docking capability was enhanced. Molecular docking analysis demonstrated that apigenin binds to the ATP-binding site of P-gp through a hydrogen bond with LYS408 and therefore, interferes with binding and cleavage of ATP which are vital for the function of ABC transporters (Saeed et al., 2015). Comparing flavonols to their corresponding flavones such as kaempferol to apigenin, better docking properties have been found in flavonols due to the number of hydrogen bonds (Badhan and Penny, 2006). A number of naringenin derivatives such as hydrazones and azines were produced by Ferreira et al. (2018) to achieve an improved MDR reversal in P-gp and BCRP. There was a high selectivity for most members of these two groups. It has been shown that the active compounds bind to hydrophobic residues such as transmembrane helix 4 and 5 in the center of an active pocket of BCRP similar to fumitremorgin C, a common inhibitor of BCRP. The hydrazone of these derivatives, a continuation of imine, is located in a pocket in π- π interaction with Phe515 and a dipole-dipole interaction with Met541. The B-ring is in another lipophilic bag made of Phe545, Pro574 and Val516. An improvement in the interaction between the transporter MRP1 and the carbohydrazide derivatives of flavonones due to the resulting flexibility was also observed (Ferreira et al., 2018).

Conclusions and Future Perspectives

Due to the increase of cancer cases and restrictions in therapy owing to the degree of harmfulness, effectiveness and the associated high costs, the development of new substances with less side effects and higher efficacy is required. So far, many structures from the plant kingdom have been discovered and used, such as, diterpene derivatives as taxanes and vinca alkaloids are prime examples with regard to antitumor therapy. Therefore, numerous secondary metabolites which already had positive effect on cell lines should be taken into account for further investigations, which is why we have tried to list them extensively in our tables.

Many phytochemicals including alkaloids, flavonoids, curcuminoids, stilbenoids, terpenes, carotenoids, lignans, and polyketides were examined for their pharmacological activity against MDR. In most of the studies it was possible to differentiate between more effective and less effective molecules. As the next step these molecules must be further studied to determine molecular mechanisms and to identify the pharmacophores. Some valuable results have been provided by structure-activity relationship studies or in silico modeling as shown in this article. Subtances which were superior to others should be selected for further research, so possible lead molecules can be developed. A further step to increase efficacy could be the use of new drug delivery methods and controlled release as with nanotechnologies. As shown in this review, the combination of two and more modulators of differing structures and mode of actions together with chemotherapeutics is another interesting approach. The resulting additive, but above all synergistic effects can be of great importance. They would allow reducing the dose of chemotherapeutics resulting in less side effects and a higher compliance of patients.

Summin up, many phytochemicals in the group of alkaloids, flavonoids, curcuminoids, stilbenoids, terpenes, carotenoids, lignans, and polyketides have been investigated for MDR-reversing activity. Phytochemicals can be a promising source of adjuvant chemicals against cancer, not at least because of their generally low cytotoxicity in the human body. The adjuvant uses of MDR reversing phytochemicals in combination with anticancer drugs may improve the treatment of multidrug resistant cancer types. The present review summarized reports of several secondary metabolites that are capable of synergistically reversing MDR and inhibiting chemotherapy-resistant cancer cells by affecting transporter activity and the expression of ABC transporter genes. Synergism would allow reducing the dose of chemotherapeutics resulting in less side effects and a higher compliance of patients. The efficacy of phytochemicals needs to be confirmed clinically, but nevertheless they already can be considered as the fourth generation of ABC transporter modulators.

Funding

Ruprecht-Karls-Universität Heidelberg provided financial support within Open-Access Publishing Program.

Statements

Author contributions

BT and IS performed the literature search and wrote the first draft of the manuscript. MW revised and edited the manuscript. All the authors approved the final version of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

ADR, adriamycin; CPT, camptothecin; DOX, doxorubicin; DNR, daunorubicin; DTN, digitonin; EGC, epigallocatechin; EGCG, epigallocatechin gallate; MDR, multidrug resistance; MTX, mitoxantrone; P-gp, P-glycoprotein; PTX, paclitaxel; Rh-123, rhodamine 123; VBL, vinblastine; VCR, vincristine; BCRP, breast cancer resistance protein; MRP, multidrug resistance protein.

References

  • 1

    AktoriesK.FörstermannU.HofmannF. B.StarkeK. (2017). Allgemeine und spezielle Pharmakologie und Toxikologie: Begründet von W. Forth. Eds. HenschlerD.RummelW. (München, Germany: Urban & Fischer Verlag/Elsevier GmbH).

  • 2

    AlamolhodaeiN. S.TsatsakisA. M.RamezaniM.HayesA. W.KarimiG. (2017). Resveratrol as MDR reversion molecule in breast cancer: An overview. Food Chem. Toxicol.103, 223232. doi: 10.1016/j.fct.2017.03.024

  • 3

    AmpasavateC.SotanaphunU.PhattanawasinP.PiyapolrungrojN. (2010). Effects of Curcuma spp. on P-glycoprotein function. Phytomedicine17, 506512. doi: 10.1016/j.phymed.2009.09.004

  • 4

    AroraA.ShuklaY. (2003). Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Canc. Lett.189, 167173. doi: 10.1016/S0304-3835(02)00550-5

  • 5

    BadhanR.PennyJ. (2006). In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur. J. Med. Chem.41, 285295. doi: 10.1016/j.ejmech.2005.11.012

  • 6

    BaumannT. W.FrischknechtP. M. (1988). “Purines,” in Phytochemicals in Plant Cell Cultures (San Diego, USA: Academic Press), 403417.

  • 7

    BayetC.FazioC.DarbourN.BergerO.RaadI.ChaboudA.et al. (2007). Modulation of P-glycoprotein activity by acridones and coumarins from Citrus sinensis. Phytother. Res.21, 386390. doi: 10.1002/ptr.2081

  • 8

    BerekL.SzaboD.PetriI. B.ShoyamaY.LinY. H.MolnárJ. (2001). Effects of naturally occurring glucosides, solasodine glucosides, ginsenosides and parishin derivatives on multidrug resistance of lymphoma cells and leukocyte functions. Vivo15, 151156.

  • 9

    BernsteinC.BernsteinH.PayneC. M.GarewalH. (2002). DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat. Res. Rev. Mutat.511, 145178. doi: 10.1016/S1383-5742(02)00009-1

  • 10

    BlochK. E. (1983). Sterol, structure and membrane function. Crit. Rev. Biochem.14, 4792. doi: 10.3109/10409238309102790

  • 11

    BorstP.EversR.KoolM.WijnholdsJ. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Canc. Inst.92, 12951302. doi: 10.1093/jnci/92.16.1295

  • 12

    BorthwickA. D.LiddleJ. (2011). The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. Med. Res. Rev.31, 576604. doi: 10.1002/med.20193

  • 13

    BoumendjelA.Di PietroA.DumontetC.BarronD. (2002). Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev.22, 512529. doi: 10.1002/med.10015

  • 14

    BrownG. A.McPhersonJ. P.GuL.HedleyD. W.TosoR.DeucharsK. L.et al. (1995). Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Canc. Res.55, 7882.

  • 15

    CaiX.ChenF. Y.HanJ. Y.GuC. H.ZhongH.OuyangR. R. (2004). Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM. Chin. J. Canc.23, 16111615.

  • 16

    CaiX.ChenF. Y.HanJ. Y.GuC. H.ZhongH.TengY.et al. (2005). Reversal of multidrug resistance of HL-60 adriamycin resistant leukemia cell line by quercetin and its mechanisms. Chin. J. Oncol.27, 326329.

  • 17

    CaoJ.ChenX.LiangJ.YuX. Q.XuA. L.ChanE.et al. (2007). Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. Drug Metabol. Dispos.35, 539553. doi: 10.1124/dmd.106.010801

  • 18

    CaoZ.WrightM.ChengJ.HuangX.LiuL.WuL.et al. (2014). The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance. Oncol. Rep.32, 12111217. doi: 10.3892/or.2014.3326

  • 19

    ChanmahasathienW.AmpasavateC.GregerH.LimtrakulP. (2011). Stemona alkaloids, from traditional Thai medicine, increase chemosensitivity via P-glycoprotein-mediated multidrug resistance. Phytomedicine18, 199204. doi: 10.1016/j.phymed.2010.07.014

  • 20

    ChangH. Y.PanK. L.MaF. C.JiaoX. Y.ZhuH. F.LiuJ. H.et al. (2006). The Study on Reversing Mechanism of Multidrug Resistance of K562/A02 Cell Line by Curcumin and Erythromycin. Chin. J. Hematol.27, 254258.

  • 21

    ChenY. W.LinG. J.ChuangY. P.ChiaW. T.HuengD. Y.LinC. K.et al. (2010). Triptolide circumvents drug-resistant effect and enhances 5-fluorouracil antitumor effect on KB cells. Anti Canc. Drugs21, 502513. doi: 10.1097/CAD.0b013e328337337c

  • 22

    ChenZ.ShiT.ZhangL.ZhuP.DengM.HuangC.et al. (2016). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Canc. Lett.370, 153164. doi: 10.1016/j.canlet.2015.10.010

  • 23

    ChenZ.HuangC.MaT.JiangL.TangL.ShiT.et al. (2018). Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells. Phytomedicine43, 3745. doi: 10.1016/j.phymed.2018.03.040

  • 24

    ChengY. H.QiJ.XiongD. S.LiuJ. W.QiS. L.PanB.et al. (2006). Reversal of multidrug resistance in drug-resistant human breast cancer cell line MCF-7/ADR by calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine. Acta Academiae Medicinae Sinicae28, 164168.

  • 25

    ChoiC. H.KangG.MinY. D. (2003). Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med.69, 235240. doi: 10.1055/s-2003-38483

  • 26

    ChungS. Y.SungM. K.KimN. H.JangJ. O.GoE. J.LeeH. J. (2005). Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch. Pharmacal Res.28, 823828. doi: 10.1007/BF02977349

  • 27

    CihalovaD.HofmanJ.CeckovaM.StaudF. (2013). Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. PloS One8, e83467. doi: 10.1371/journal.pone.0083467

  • 28

    ColeyH. M. (2008). Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Canc. Treat. Rev.34, 378390. doi: 10.1016/j.ctrv.2008.01.007

  • 29

    CollinG.HökeH. (2000). “Quinoline and isoquinoline,” in Ullmann"s Encyclopedia of Industrial Chemistry (New Jersey, USA: Wiley-VCH).

  • 30

    ConseilG.Baubichon-CortayH.DayanG.JaultJ. M.BarronD.Di PietroA. (1998). Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci.95, 98319836. doi: 10.1073/pnas.95.17.9831

  • 31

    CörD.KnezŽ.Knez HrnčičM. (2018). Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of Ganoderma lucidum terpenoids and polysaccharides: A review. Molecules23, 649. doi: 10.3390/molecules23030649

  • 32

    CripeL. D.UnoH.PaiettaE. M.LitzowM. R.KetterlingR. P.BennettJ. M.et al. (2010). Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood116, 40774085. doi: 10.1182/blood-2010-04-277269

  • 33

    CsekeL. J.KirakosyanA.KaufmanP. B.WarberS. L.DukeJ. A.BrielmannH. L. (2006). Natural Products from Plants. 2nd Ed (Boca Raton, USA: CRC Press), ISBN: 0-8493-2976-0.

  • 34

    da Graça RochaG.SimoesM.LucioK. A.OliveiraR. R.KaplanM. A. C.GattassC. R. (2007). Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines. Bioorg. Med. Chem.15, 73557360. doi: 10.1016/j.bmc.2007.07.020

  • 35

    DačevićM.IsakovićA.Podolski-RenićA.IsakovićA. M.StankovićT.MiloševićZ.et al. (2013). Purine nucleoside analog-sulfinosine modulates diverse mechanisms of cancer progression in multi-drug resistant cancer cell lines. PloS One8, e54044. doi: 10.1371/journal.pone.0054044

  • 36

    DaenenS.van der HoltB.VerhoefG. E.LöwenbergB.WijermansP. W.HuijgensP. C.et al. (2004). Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: A randomised phase II trial from HOVON, the Dutch–Belgian Haemato-Oncology Working Group for adults. Leuk. Res.28, 10571067. doi: 10.1016/j.leukres.2004.03.001

  • 37

    De CastroW. V.Mertens-TalcottS.DerendorfH.ButterweckV. (2008). Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J. Agr. Food Chem.56, 48404845. doi: 10.1021/jf0728451

  • 38

    de SaA.FernandoR.BarreiroE. J.FragaM.AlbertoC. (2009). From nature to drug discovery: the indole scaffold as a ‘privileged structure'. Mini Rev. Med. Chem.9, 782793. doi: 10.2174/138955709788452649

  • 39

    Di PietroA.ConseilG.Perez-VictoriaJ. M.DayanG.Baubichon-CortayH.TrompierD.et al. (2002). Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell. Mol. Life Sci.59, 307322. doi: 10.1007/s00018-002-8424-8

  • 40

    DongQ. H.ZhengS.XuR. Z.LuQ.HeL. (2004). Study on effect of berbamine on multidrug resistance leukemia K562/Adr cells. Chin. J. Integrated Tradit. West. Med.24, 820822.

  • 41

    DoyleL. A.YangW.AbruzzoL. V.KrogmannT.GaoY.RishiA. K.et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci.95, 1566515670. doi: 10.1073/pnas.95.26.15665

  • 42

    DuarteN.GyémántN.AbreuP. M.MolnárJ.FerreiraM. J. U. (2006). New macrocyclic lathyrane diterpenes, from Euphorbia lagascae, as inhibitors of multidrug resistance of tumour cells. Planta Med.72, 162168. doi: 10.1055/s-2005-873196

  • 43

    DuarteN.JárdánházyA.MolnárJ.HilgerothA.FerreiraM. J. U. (2008). Synergistic interaction between p-glycoprotein modulators and epirubicine on resistant cancer cells. Bioorg. Med. Chem.16, 93239330. doi: 10.1016/j.bmc.2008.08.071

  • 44

    DurmusS.HendrikxJ. J.SchinkelA. H. (2015). “Apical ABC transporters and cancer chemotherapeutic drug disposition,” in Advances in Cancer Research (San Diego, USA: Academic Press), 141.

  • 45

    EfferthT.DaveyM.OlbrichA.RückerG.GebhartE.DaveyR. (2002). Activity of drugs from traditional Chinese medicine toward sensitive and MDR1-or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis.28, 160168. doi: 10.1006/bcmd.2002.0492

  • 46

    EidS. Y.El-ReadiM. Z.WinkM. (2012). Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine19, 977987. doi: 10.1016/J.PHYMED.2012.05.010

  • 47

    EidS. Y.El-ReadiM. Z.EldinE. E. M. N.FataniS. H.WinkM. (2013). Influence of combinations of digitonin with selected phenolics, terpenoids, and alkaloids on the expression and activity of P-glycoprotein in leukaemia and colon cancer cells. Phytomedicine21, 4761. doi: 10.1016/J.PHYMED.2013.07.019

  • 48

    El-ReadiM. Z.HamdanD.FarragN.El-ShazlyA.WinkM. (2010). Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur. J. Pharmacol.626, 139145. doi: 10.1016/j.ejphar.2009.09.040

  • 49

    El-ReadiM. Z.EidS.AbdelghanyA. A.Al-AmoudiH. S.EfferthT.WinkM. (2019). Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes. Phytomedicine55, 269281. doi: 10.1016/J.PHYMED.2018.06.046

  • 50

    FantiniM.BenvenutoM.MasuelliL.FrajeseG. V.TresoldiI.ModestiA.et al. (2015). In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: Perspectives on cancer treatment. Int. J. Mol. Sci.16, 92369282. doi: 10.3390/ijms16059236

  • 51

    FarabegoliF.PapiA.BartoliniG.OstanR.OrlandiM. (2010). (-)-Epigallocatechin-3-gallate downregulates P-gp and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine17, 356362. doi: 10.1016/j.phymed.2010.01.001

  • 52

    FerreiraR. J.BaptistaR.MorenoA.MadeiraP. G.KhonkarnR.Baubichon-CortayH.et al. (2018). Optimizing the flavanone core toward new selective nitrogen-containing modulators of ABC transporters. Future Med. Chem.10, 725741. doi: 10.4155/fmc-2017-0228

  • 53

    FongW. F.WanC. K.ZhuG. Y.ChattopadhyayA.DeyS.ZhaoZ.et al. (2007). Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Med.73, 212220. doi: 10.1055/s-2007-967120

  • 54

    GadeD. R.MakkapatiA.YarlagaddaR. B.PetersG. J.SastryB. S.PrasadV. R. (2018). Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies. Comput. Biol. Chem.74, 6375. doi: 10.1016/j.compbiolchem.2018.02.014

  • 55

    GanC. Y.LowY. Y.EtohT.HayashiM.KomiyamaK.KamT. S. (2009). Leuconicines A− G and (−)-Eburnamaline, Biologically Active Strychnan and Eburnan Alkaloids from Leuconotis. J. Nat. Prod.72, 20982103. doi: 10.1021/np900576b

  • 56

    GanC. Y.YoganathanK.SimK. S.LowY. Y.LimS. H.KamT. S. (2014). Corynanthean, eburnan, secoleuconoxine, and pauciflorine alkaloids from Kopsia pauciflora. Phytochemistry108, 234242. doi: 10.1016/j.phytochem.2014.09.014

  • 57

    GantaS.AmijiM. (2009). Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm.6, 928939. doi: 10.1021/mp800240j

  • 58

    GaoN.ZhangY.MaoJ. Q.LiG. Q.ZhouW.GaoB.et al. (2008). Effects of some traditional Chinese drugs on Mdr1 gene and its expression product in K562/A02 cells. J. Exp. Hematol.16, 785789.

  • 59

    GawaliV. S.SimeonovS.DrescherM.KnottT.ScheelO.KudoloJ.et al. (2017). C2-modified sparteine derivatives are a new class of potentially long-acting sodium channel blockers. ChemMedChem12, 18191822. doi: 10.1002/cmdc.201700568

  • 60

    GilbertK. (2001). Review of Plant Secondary Metabolism, by David S. Seigler. Plant Growth Regul.34, 149. doi: 10.1023/A:1013354907356

  • 61

    GuoQ.NanX. X.YangJ. R.YiL.LiangB. L.WeiY. B.et al. (2013). Triptolide inhibits the multidrug resistance in prostate cancer cells via the downregulation of MDR1 expression. Neoplasma60, 598604. doi: 10.4149/neo_2013_077

  • 62

    GyémántN.TanakaM.AntusS.HohmannJ.CsukaO.MándokyL.et al. (2005). andIn vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells. Vivo19, 367374.

  • 63

    GyémántN.TanakaM.MolnárP.DeliJ.MándokyL.MolnárJ. (2006). Reversal of multidrug resistance of cancer cells in vitro: modification of drug resistance by selected carotenoids. Anticancer Res.26, 367374.

  • 64

    HänselR.SticherO. (Eds.) (2009). Pharmakognosie-Phytopharmazie (Heidelberg, Germany: Springer-Verlag).

  • 65

    HanY.TanT. M. C.LimL. Y. (2006). Effects of capsaicin on P-gp function and expression in Caco-2 cells. Biochem. Pharmacol.71, 17271734. doi: 10.1016/j.bcp.2006.03.024

  • 66

    HeL.ZhaoC.YanM.ZhangL. Y.XiaY. Z. (2009). Inhibition of P-glycoprotein function by procyanidine on blood–brain barrier. Phytother. Res.23, 933937. doi: 10.1002/ptr.2781

  • 67

    HeL.YangJ.HuL. (2010). Transmembrane transport activity of paclitaxel regulated by fangchinoline in MDR1-mDCK II cells. China J. Chin. Materia Med.35, 14781481.

  • 68

    HegdeR.ThimmaiahP.YerigeriM. C.KrishnegowdaG.ThimmaiahK. N.HoughtonP. J. (2004). Anti-calmodulin acridone derivatives modulate vinblastine resistance in multidrug resistant (MDR) cancer cells. Eur. J. Med. Chem.39, 161177. doi: 10.1016/j.ejmech.2003.12.001

  • 69

    HsiaoS. H.LuY. J.YangC. C.TuoW. C.LiY. Q.HuangY. H.et al. (2016). Hernandezine, a bisbenzylisoquinoline alkaloid with selective inhibitory activity against multidrug-resistance-linked ATP-binding cassette drug transporter ABCB1. J. Nat. Prod.79, 21352142. doi: 10.1021/acs.jnatprod.6b00597

  • 70

    HuY. J.ShenX. L.LuH. L.ZhangY. H.HuangX. A.FuL. C.et al. (2008). Tenacigenin B derivatives reverse P-glycoprotein-mediated multidrug resistance in HepG2/Dox cells. J. Nat. Prod.71, 10491051. doi: 10.1021/np070458f

  • 71

    HuangM.JinJ.SunH.LiuG. T. (2008). Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus schizandrae. Canc. Chemother. Pharmacol.62, 10151026. doi: 10.1007/s00280-008-0691-0

  • 72

    HuangF.WuX. N.ChenJ. I. E.WangW. X.LuZ. F. (2014). Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells. Exp. Ther. Med.7, 16111616. doi: 10.3892/etm.2014.1662

  • 73

    IkegawaT.UshigomeF.KoyabuN.MorimotoS.ShoyamaY.NaitoM.et al. (2000). Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Canc. Lett.160, 2128. doi: 10.1016/S0304-3835(00)00549-8

  • 74

    ImaiY.TsukaharaS.AsadaS.SugimotoY. (2004). Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Canc. Res.64, 43464352. doi: 10.1158/0008-5472.CAN-04-0078

  • 75

    IncardonaJ. P.GaffieldW.KapurR. P.RoelinkH. (1998). The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development125, 35533562.

  • 76

    IvanovaA.SerlyJ.DinchevD.OcsovszkiI.KostovaI.MolnárJ. (2009). Screening of some saponins and phenolic components of Tribulus terrestris and Smilax excelsa as MDR modulators. Vivo23, 545550.

  • 77

    IvanovaA.SerlyJ.ChristovV.StamboliyskaB.MolnaárJ. (2011). Alkaloids derived from genus Veratrum and Peganum of Mongolian origin as multidrug resistance inhibitors of cancer cells. Fitoterapia82, 570575. doi: 10.1016/J.FITOTE.2011.01.015

  • 78

    JonesP. M.GeorgeA. M. (2002). Mechanism of ABC transporters: a molecular dynamics simulation of a well characterized nucleotide-binding subunit. Proc. Natl. Acad. Sci.99, 1263912644. doi: 10.1073/pnas.152439599

  • 79

    KamT. S.SubramaniamG.SimK. M.YoganathanK.KoyanoT.ToyoshimaM.et al. (1998). Reversal of multidrug resistance (MDR) by aspidofractinine-type indole alkaloids. Bioorg. Med. Chem. Lett.8, 27692772. doi: 10.1016/S0960-894X(98)00486-7

  • 80

    KamathK.WilsonL.CabralF.JordanM. A. (2005). βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem.280, 1290212907. doi: 10.1074/jbc.M414477200

  • 81

    KasaianJ.MosaffaF.BehravanJ.MasulloM.PiacenteS.GhandadiM.et al. (2015). Reversal of P-glycoprotein-mediated multidrug resistance in MCF-7/Adr cancer cells by sesquiterpene coumarins. Fitoterapia103, 149154. doi: 10.1016/j.fitote.2015.03.025

  • 82

    KashiwadaY.NishimuraK.KurimotoS.TakaishiY. (2011). New 29-nor-cycloartanes with a 3,4-seco- and a novel 2,3-seco-structure from the leaves of Sinocalycanthus chinensis. Bioorg. Med. Chem.19, 27902796. doi: 10.1016/j.bmc.2011.03.055

  • 83

    KavallarisM.TaitA. S.WalshB. J.HeL.HorwitzS. B.NorrisM. D.et al. (2001). Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Canc. Res.61, 58035809.

  • 84

    KellyR. J.DraperD.ChenC. C.RobeyR. W.FiggW. D.PiekarzR. L.et al. (2011). A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin. Canc. Res.17, 569580. doi: 10.1158/1078-0432.CCR-10-1725

  • 85

    KimS. W.KwonH. Y.ChiD. W.ShimJ. H.ParkJ. D.LeeY. H.et al. (2003). Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem. Pharmacol.65, 7582. doi: 10.1016/S0006-2952(02)01446-6

  • 86

    KimE.-H.MinH.-Y.ChungH.-J.SongJ.ParkH.-J.KimS.et al. (2012). Anti-proliferative activity and suppression of P-glycoprotein by (–)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells. Food Chem. Toxicol.50, 10601065. doi: 10.1016/J.FCT.2011.11.008

  • 87

    KitagawaS.NabekuraT.KamiyamaS. (2004). Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol.56, 10011005. doi: 10.1211/0022357044003

  • 88

    KitagawaS.NabekuraT.TakahashiT.NakamuraY.SakamotoH.TanoH.et al. (2005). Structure–activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol. Pharm. Bull.28, 22742278. doi: 10.1248/bpb.28.2274

  • 89

    KitagawaS.TakahashiT.NabekuraT.TachikawaE.HasegawaH. (2007). Inhibitory effects of ginsenosides and their hydrolyzed metabolites on daunorubicin transport in KB-C2 cells. Biol. Pharm. Bull.30, 19791981. doi: 10.1248/bpb.30.1979

  • 90

    KoesR. E.QuattrocchioF.MolJ. N. (1994). The flavonoid biosynthetic pathway in plants: function and evolution. BioEssays16, 123132. doi: 10.1002/bies.950160209

  • 91

    KönigJ.HartelM.NiesA. T.MartignoniM. E.GuoJ.BüchlerM. W.et al. (2005). Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Canc.115, 359367. doi: 10.1002/ijc.20831

  • 92

    KörperS.WinkM.FinkR. H. (1998). Differential effects of alkaloids on sodium currents of isolated single skeletal muscle fibers. FEBS Lett.436, 251255. doi: 10.1016/S0014-5793(98)01135-1

  • 93

    Kukula-KochW. A.WidelskiJ. (2017). “Alkaloids,” in Pharmacognosy (San Diego, USA: Academic Press), 163198.

  • 94

    KurimotoS. I.KashiwadaY.LeeK. H.TakaishiY. (2011a). Triterpenes and a triterpene glucoside from Dysoxylum cumingianum. Phytochemistry72, 22052211. doi: 10.1016/j.phytochem.2011.08.002

  • 95

    KurimotoS. I.KashiwadaY.Morris-NatschkeS. L.LeeK. H.TakaishiY. (2011b). Dyscusins A—C, three new steroids from the leaves of Dysoxylum cumingianum. Chem. Pharm. Bull.59, 13031306. doi: 10.1248/cpb.59.1303

  • 96

    LeiY.TanJ.WinkM.MaY.LiN.SuG. (2013). An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo W.T. Wang inhibits P-glycoprotein and multidrug resistance-associate protein 1. Food Chem.136, 11171121. doi: 10.1016/j.foodchem.2012.09.059

  • 97

    LemmerB.BruneK. (2004). Pharmakotherapie (Heidelberg, Germany: Springer-Verlag).

  • 98

    LiL.StantonJ. D.TolsonA. H.LuoY.WangH. (2009). Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharmaceut. Res.26, 872. doi: 10.1007/s11095-008-9788-8

  • 99

    LiY.WangQ.YaoX.LiY. (2010). Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor-and pregnane X receptor-mediated pathways. Eur. J. Pharmacol.640, 4654. doi: 10.1016/j.ejphar.2010.05.017

  • 100

    LiS.LeiY.JiaY.LiN.WinkM.MaY. (2011). Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells. Phytomedicine19, 8387. doi: 10.1016/j.phymed.2011.06.031

  • 101

    LiH.KrstinS.WangS.WinkM. (2018a). Capsaicin and piperine can overcome multidrug resistance in cancer cells to doxorubicin. Molecules23, 557. doi: 10.3390/molecules23030557

  • 102

    LiH.KrstinS.WinkM. (2018b). Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin. Phytomedicine50, 213222. doi: 10.1016/j.phymed.2018.09.169

  • 103

    LiangG.TangA.LinX.LiL.ZhangS.HuangZ.et al. (2010). Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int. J. Oncol.37, 111123. doi: 10.3892/ijo_00000659

  • 104

    LiaoD.ZhangW.GuptaP.LeiZ. N.WangJ. Q.CaiC. Y.et al. (2019). Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. Molecules24, 4383. doi: 10.3390/molecules24234383

  • 105

    LimtrakulP.AnuchapreedaS.BuddhasukhD. (2004). Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Canc.4, 13. doi: 10.1186/1471-2407-4-13

  • 106

    LimtrakulP.ChearwaeW.ShuklaS.PhisalphongC.AmbudkarS. V. (2007). Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell. Biochem.296, 8595. doi: 10.1007/s11010-006-9302-8

  • 107

    LinH. L.LiuT. Y.LuiW. Y.ChiC. W. (1999a). Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. Canc. Interdiscipl. Int. J. Am. Canc. Soc85, 19371942. doi: 10.1002/(SICI)1097-0142(19990501)85:9<1937::AID-CNCR9>3.0.CO;2-F

  • 108

    LinH.-L.LiuT.-Y.WuC.-W.ChiC.-W. (1999b). Berberine modulates expression of MDR1 gene product and the responses of digestive track cancer cells to paclitaxel. Br. J. Canc.81, 416422. doi: 10.1038/sj.bjc.6690710

  • 109

    LiuC. M.KaoC. L.TsengY. T.LoY. C.ChenC. Y. (2017). Ginger phytochemicals inhibit cell growth and modulate drug resistance factors in docetaxel resistant prostate cancer cell. Molecules22, 1477. doi: 10.3390/molecules22091477

  • 110

    LuJ. J.DangY. Y.HuangM.XuW. S.ChenX. P.WangY. T. (2012). Anti-cancer properties of terpenoids isolated from Rhizoma curcumae – a review. J. Ethnopharmacol.143, 406411. doi: 10.1016/j.jep.2012.07.009

  • 111

    LuW. D.QinY.YangC.LiL. (2013). Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo. Clinics68, 694701. doi: 10.6061/clinics/2013(05)18

  • 112

    MaY.WinkM. (2008). Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells. Phytomedicine15, 754758. doi: 10.1016/j.phymed.2007.11.028

  • 113

    MaY.WinkM. (2010). The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother. Res.24, 146149. doi: 10.1002/ptr.2860

  • 114

    MaW.FengS.YaoX.YuanZ.LiuL.XieY. (2015). Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells. Sci. Rep.5, 18789. doi: 10.1038/srep18789

  • 115

    MartinsA.VasasA.SchelzZ.ViveirosM.MolnárJ.HohmannJ.et al. (2010). Constituents of Carpobrotus edulis inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells. Anticancer Res.30, 829835.

  • 116

    MayurY. C.PadmaT.ParimalaB. H.ChandramouliK. H.JagadeeshS.GowdaN. M.et al. (2006). Sensitization of multidrug resistant (MDR) cancer cells to vinblastine by novel acridones: correlation between anti-calmodulin activity and anti-MDR activity. Med. Chem.2, 6377. doi: 10.2174/157340606775197732

  • 117

    MayurY. C. (2015). “Designing of drug molecules for reversing P-glycoprotein (Pgp) mediated drug resistance in cancer cells,” in Frontiers in Anti-Cancer Drug Discovery. Eds. Ata-ur-R.ChaudharyM. I. (Sharjah, UAE: Bentham Science Publishers), 157198.

  • 118

    MiQ.CuiB.SilvaG. L.LantvitD.LimE.ChaiH.et al. (2001). Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Canc. Res.61, 40304037.

  • 119

    MiQ.CuiB.SilvaG. L.LantvitD.LimE.ChaiH.et al. (2002). Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay. Canc. Lett.184, 1320. doi: 10.1016/S0304-3835(02)00202-1

  • 120

    MinY. D.ChoiS. U.LeeK. R. (2006). Aporphine alkaloids and their reversal activity of multidrug resistance (MDR) from the stems and rhizomes of Sinomenium acutum. Arch. Pharm. Res.29, 627632. doi: 10.1007/BF02968246

  • 121

    MinY. D.KwonH. C.YangM. C.LeeK. H.ChoiS. U.LeeK. R. (2007). Isolation of limonoids and alkaloids from Phellodendron amurense and their multidrug resistance (MDR) reversal activity. Arch. Pharmacal Res.30, 5863. doi: 10.1007/BF02977779

  • 122

    MitaniY.SatakeK.TsukamotoM.NakamuraI.KadiogluO.TeruyaT.et al. (2018). Epimagnolin A, a tetrahydrofurofuranoid lignan from Magnolia fargesii, reverses ABCB1-mediated drug resistance. Phytomedicine51, 112119. doi: 10.1016/j.phymed.2018.06.030

  • 123

    MohanlalR.SunY.KloeckerG.FeinsteinT.ShiY.HanB.et al. (2019). P2. 01-23 DUBLIN-3, a phase (Ph) III trial comparing the plinabulin (P)/docetaxel (D) combination with D alone in stage IIIb/IV NSCLC. J. Thorac. Oncol.14, S647S648. doi: 10.1016/j.jtho.2019.08.1367

  • 124

    MolnárJ.SzaboD.PusztaiR.MucsiI.BerekL.OcsovszkiI.et al. (2000). Membrane associated antitumor effects of crocine-, ginsenoside-and cannabinoid derivates. Anticancer Res.20, 861867.

  • 125

    MolnárJ.GyémántN.TanakaM.HohmannJ.Bergmann-LeitnerE.MolnárP.et al. (2006). Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. Curr. Pharmaceut. Des.12, 287311. doi: 10.2174/138161206775201893

  • 126

    MolnárJ.EngiH.HohmannJ.MolnárP.DeliJ.WesolowskaO.et al. (2010). Reversal of multidrug resistance by natural substances from plants. Curr. Top. Med. Chem.10, 17571768. doi: 10.2174/156802610792928103

  • 127

    MoussaviM.HaddadF.RassouliF. B.IranshahiM.SoleymanifardS. (2017). Synergy between auraptene, ionizing radiation, and anticancer drugs in colon adenocarcinoma cells. Phytother. Res.31, 13691375. doi: 10.1002/ptr.5863

  • 128

    MurahariM.KharkarP. S.LonikarN.MayurY. C. (2017). Design, synthesis, biological evaluation, molecular docking and QSAR studies of 2, 4-dimethylacridones as anticancer agents. Eur. J. Med. Chem.130, 154170. doi: 10.1016/j.ejmech.2017.02.022

  • 129

    NabekuraT.KamiyamaS.KitagawaS. (2005). Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun.327, 866870. doi: 10.1016/j.bbrc.2004.12.081

  • 130

    NabekuraT.YamakiT.UenoK.KitagawaS. (2008a). Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Canc. Chemother. Pharmacol.62, 867873. doi: 10.1007/s00280-007-0676-4

  • 131

    NabekuraT.YamakiT.KitagawaS. (2008b). Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1. Eur. J. Pharmacol.600, 4549. doi: 10.1016/j.ejphar.2008.10.025

  • 132

    NabekuraT.YamakiT.UenoK.KitagawaS. (2008c). Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem. Biophys. Res. Commun.369, 363368. doi: 10.1016/j.bbrc.2008.02.026

  • 133

    NabekuraT.YamakiT.HiroiT.UenoK.KitagawaS. (2010). Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacol. Res.61, 259263. doi: 10.1016/j.phrs.2009.11.010

  • 134

    NajarI. A.SachinB. S.SharmaS. C.SattiN. K.SuriK. A.JohriR. K. (2010). Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother. Res.24, 454458. doi: 10.1002/ptr.2951

  • 135

    NamanjaH. A.EmmertD.PiresM. M.HrycynaC. A.ChmielewskiJ. (2009). Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. Biochem. Biophys. Res. Commun.388, 672676. doi: 10.1016/J.BBRC.2009.08.056

  • 136

    NetoS.DuarteN.PedroC.SpenglerG.MolnárJ.FerreiraM. J. U. (2019). Effective MDR reversers through phytochemical study of Euphorbia boetica. Phytochem. Anal.30, 498511. doi: 10.1002/pca.2841

  • 137

    NguyenH.ZhangS.MorrisM. E. (2003). Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharmaceut. Sci.92, 250257. doi: 10.1002/jps.10283

  • 138

    NieriP.RomitiN.AdinolfiB.ChiccaA.MassarelliI.ChieliE. (2006). Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br. J. Pharmacol.148, 682. doi: 10.1038/sj.bjp.0706778

  • 139

    O'ConnorP. M.JackmanJ.BaeI.MyersT. G.FanS.MutohM.et al. (1997). Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Canc. Res.57, 42854300.

  • 140

    OhtaniH.IkegawaT.HondaY.KohyamaN.MorimotoS.ShoyamaY.et al. (2007). Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells. Pharmaceut. Res.24, 19361943. doi: 10.1007/s11095-007-9320-6

  • 141

    OsmanA. M. G.ChittiboyinaA. G.KhanI. A. (2013). “Foodborne infections and intoxications: Chapter 32,” in Plant Toxins (San Diego, USA: Academic Press).

  • 142

    PancheA. N.DiwanA. D.ChandraS. R. (2016). Flavonoids: an overview. J. Nutr. Sci.5 (E47), 115. doi: 10.1017/jns.2016.41

  • 143

    PearceH. L.SafaA. R.BachN. J.WinterM. A.CirtainM. C.BeckW. T. (1989). Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl. Acad. Sci. U.S.A.86, 51285132. doi: 10.1073/PNAS.86.13.5128

  • 144

    PiresM. M.EmmertD.HrycynaC. A.ChmielewskiJ. (2009). Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol. Pharmacol.75, 92100. doi: 10.1124/mol.108.050492

  • 145

    ReisM. A.AhmedO. B.SpenglerG.MolnárJ.LageH.FerreiraM. J. U. (2016). Jatrophane diterpenes and cancer multidrug resistance–ABCB1 efflux modulation and selective cell death induction. Phytomedicine23, 968978. doi: 10.1016/j.phymed.2016.05.007

  • 146

    RethyB.HohmannJ.MinoricsR.VargaA.OcsovszkiI.MolnárJ.et al. (2008). Antitumour properties of acridone alkaloids on a murine lymphoma cell line. Anticancer Res.28, 27372743.

  • 147

    Reyes-EsparzaJ.MoralesA. I. G.González-MayaL.Rodríguez-FragosoL. (2015). (-)-Epigallocatechin-3-gallate modulates the activity and expression of P-glycoprotein in breast cancer cells. J. Pharmacol. Clin. Toxicol.3, 1044.

  • 148

    RobertsM. F.WinkM. (1998). Alkaloids: Biochemistry, Ecology, and Medicinal Applications (New York, USA: Plenum Press).

  • 149

    RuenitzP. C.MoklerC. M. (1977). Analogs of sparteine. 5. antiarrhythmic activity of selected N, N'-disubstituted bispidines. J. Med. Chem.20, 16681671. doi: 10.1021/jm00222a026

  • 150

    SaeedM.KadiogluO.KhalidH.SugimotoY.EfferthT. (2015). Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking. J. Nutr. Biochem.26, 4456. doi: 10.1016/j.jnutbio.2014.09.008

  • 151

    SampsonK. E.WolfC. L.AbrahamI. (1993). Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Canc. Lett.68, 714. doi: 10.1016/0304-3835(93)90213-S

  • 152

    SergentT.GarsouS.SchautA.De SaegerS.PussemierL.Van PeteghemC.et al. (2005). Differential modulation of ochratoxin A absorption across Caco-2 cells by dietary polyphenols, used at realistic intestinal concentrations. Toxicol. Lett.159, 6070. doi: 10.1016/j.toxlet.2005.04.013

  • 153

    ShenX.ChenG.ZhuG.FongW. F. (2006). (±)-3′-O, 4′-O-dicynnamoyl-cis-khellactone, a derivative of (±)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells. Bioorg. Med. Chem.14, 71387145. doi: 10.1016/j.bmc.2006.06.066

  • 154

    ShenH.XuW.ChenQ.WuZ.TangH.WangF. (2010). Tetrandrine prevents acquired drug resistance of K562 cells through inhibition of MDR1 gene transcription. J. Canc. Res. Clin. Oncol.136, 659665. doi: 10.1007/s00432-009-0704-3

  • 155

    SheuM. T.LiouY. B.KaoY. H.LinY. K.HoH. O. (2010). A quantitative structure–activity relationship for the modulation effects of flavonoids on P-glycoprotein-mediated transport. Chem. Pharmaceut. Bull.58, 11871194. doi: 10.1248/cpb.58.1187

  • 156

    SimsteinR.BurowM.ParkerA.WeldonC.BeckmanB. (2003). Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp. Biol. Med.228, 9951003. doi: 10.1177/153537020322800903

  • 157

    SlaninováI.BřezinováL.KoubíkováL.SlaninaJ. (2009). Dibenzocyclooctadiene lignans overcome drug resistance in lung cancer cells–study of structure–activity relationship. Toxicol. Vitro23, 10471054. doi: 10.1016/j.tiv.2009.06.008

  • 158

    SmithE. W.MaibachH. I. (1995). Percutaneous Penetration Enhancers (Boca Raton, USA: CRC Press).

  • 159

    SmithE. C.KaatzG. W.SeoS. M.WarehamN.WilliamsonE. M.GibbonsS. (2007). The phenolic diterpene totarol inhibits multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother.51, 44804483. doi: 10.1128/AAC.00216-07

  • 160

    StermitzF. R.ScrivenL. N.TegosG.LewisK. (2002). Two flavonols from Artemisa annua which potentiate the activity of berberine and norfloxacin against a resistant strain of Staphylococcus aureus. Planta Med.68, 11401141. doi: 10.1055/s-2002-36347

  • 161

    SuS.ChengX.WinkM. (2015). Natural lignans from Arctium lappa modulate P-glycoprotein efflux function in multidrug resistant cancer cells. Phytomedicine22, 301307. doi: 10.1016/J.PHYMED.2014.12.009

  • 162

    SunY. F.WinkM. (2014). Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. Phytomedicine21, 11101119. doi: 10.1016/J.PHYMED.2014.04.029

  • 163

    SunH. X.XieY.YeY. P. (2009). Advances in saponin-based adjuvants. Vaccine27, 17871796. doi: 10.1016/j.vaccine.2009.01.091

  • 164

    SunJ.YeungC. A.TsangT. Y.YauE.LuoK.WuP.et al. (2012). Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-κB in R-HepG2 cell line. PloS One7, e40720. doi: 10.1371/journal.pone.0040720

  • 165

    SuzukiT.FukazawaN.San-noheK.SatoW.YanoO.TsuruoT. (1997). Structure– activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer. J. Med. Chem.40, 20472052. doi: 10.1021/jm960869l

  • 166

    SuzukiH.TanabeH.MizukamiH.InoueM. (2010). Selective regulation of multidrug resistance protein in vascular smooth muscle cells by the isoquinoline alkaloid coptisine. Biol. Pharm. Bull.33, 677682. doi: 10.1248/bpb.33.677

  • 167

    SyedS. B.CoumarM. S. (2016). P-Glycoprotein mediated multidrug resistance reversal by phytochemicals: a review of SAR & future perspective for drug design. Curr. Top. Med. Chem.16, 24842508. doi: 10.2174/1568026616666160212123814

  • 168

    SyedS. B.AryaH.FuI. H.YehT. K.PeriyasamyL.HsiehH. P.et al. (2017). Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. Sci. Rep.7, 118. doi: 10.1038/s41598-017-08062-2

  • 169

    TanakaK.IwamotoS.GonG.NoharaT.IwamotoM.TanigawaN. (2000). Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Canc. Res.6, 127134.

  • 170

    TangX.BiH.FengJ.CaoJ. (2005). Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol. Sin.26, 10091016. doi: 10.1111/j.1745-7254.2005.00149.x

  • 171

    TengY. N.SheuM. J.HsiehY. W.WangR. Y.ChiangY. C.HungC. C. (2016). β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function. Phytomedicine23, 316323. doi: 10.1016/j.phymed.2016.01.008

  • 172

    TiwaryB. K.PradhanK.NandaA. K.ChakrabortyR. (2015). Implication of quinazoline-4(3H)-ones in medicinal chemistry: a brief review. J. Chem. Biol. Ther.1, 104. doi: 10.4172/2572-0406.1000104

  • 173

    ToK. K.WuX.YinC.ChaiS.YaoS.KadiogluO. (2017). Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes. J. Ethnopharmacol.203, 110119. doi: 10.1016/j.jep.2017.03.051

  • 174

    TrockB. J.LeonessaF.ClarkeR. (1997). Multidrug resistance in breast cancer: A Meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Canc. Inst.89, 917931. doi: 10.1093/jnci/89.13.917

  • 175

    UmY.ChoS.WooH. B.KimY. K.KimH.HamJ.et al. (2008). Synthesis of curcumin mimics with multidrug resistance reversal activities. Bioorg. Med. Chem.16, 36083615. doi: 10.1016/j.bmc.2008.02.012

  • 176

    UmsumarngS.PitchakarnP.YodkeereeS.PunfaW.MapoungS.RamliR. A. (2017). Modulation of P-glycoprotein by Stemona alkaloids in human multidrug resistance leukemic cells and structural relationships. Phytomedicine34, 182190. doi: 10.1016/j.phymed.2017.08.004

  • 177

    van WykB. E.WinkM. (2017). Medicinal Plants of the World (Wallingford, UK: CABI).

  • 178

    van ZandenJ. J.WortelboerH. M.BijlsmaS.PuntA.UstaM.Bladerenv.et al. (2005). Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol.69, 699708. doi: 10.1016/j.bcp.2004.11.002

  • 179

    VasasA.SulyokE.RédeiD.ForgoP.SzabóP.ZupkóI.et al. (2011). Jatrophane diterpenes from Euphorbia esula as antiproliferative agents and potent chemosensitizers to overcome multidrug resistance. J. Nat. Prod.74, 14531461. doi: 10.1021/np200202h

  • 180

    WanC. K.ZhuG. Y.ShenX. L.ChattopadhyayA.DeyS.FongW. F. (2006). Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem. Pharmacol.72, 824837. doi: 10.1016/j.bcp.2006.06.036

  • 181

    WandelC.KimR. B.KajijiS.GuengerichF. P.WilkinsonG. R.WoodA. J. (1999). P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Canc. Res.59, 39443948.

  • 182

    WangY.CabralF. (2005). Paclitaxel resistance in cells with reduced β-tubulin. Biochim. Biophys. Acta Mol. Cell Res.1744, 245255. doi: 10.1016/j.bbamcr.2004.12.003

  • 183

    WangE. J.Barecki-RoachM.JohnsonW. W. (2002). Elevation of P-glycoprotein function by a catechin in green tea. Biochem. Biophys. Res. Commun.297, 412418. doi: 10.1016/S0006-291X(02)02219-2

  • 184

    WangC.ZhangJ. X.ShenX. L.WanC. K.TseA. K. W.FongW. F. (2004). Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. Biochem. Pharmacol.68, 843855. doi: 10.1016/j.bcp.2004.05.021

  • 185

    WangX. B.WangS. S.ZhangQ. F.LiuM.LiH. L.LiuY.et al. (2010). Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol. Rep.23, 211215. doi: 10.3892/or_00000625

  • 186

    WangS.LeiT.ZhangM. (2016). The reversal effect and its mechanisms of tetramethylpyrazine on multidrug resistance in human bladder cancer. PloS One11, e0157759. doi: 10.1371/journal.pone.0157759

  • 187

    WangX.ZhangH.ChenX. (2019). Drug resistance and combating drug resistance in cancer. Canc. Drug Resist.2, 141160. doi: 10.20517/cdr.2019.10

  • 188

    WesołowskaO.HendrichA. B.Łania-PietrzakB.WiśniewskiJ.MolnárJ.OcsovszkiI.et al. (2009). Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids. Cell. Mol. Biol. Lett.14, 199. doi: 10.2478/s11658-008-0044-3

  • 189

    WinkM.van WykB. E. (2008). Mind-Altering and Poisonous Plants of the World (Portland, USA: Timber Press).

  • 190

    WinkM.AshourM. L.El-ReadiM. Z. (2012). Secondary metabolites inhibiting ABC transporters and reversing resistance of cancer cells and fungi to cytotoxic and antimicrobial agents. Front. Microbiol.3, 130. doi: 10.3389/fmicb.2012.00130

  • 191

    WinkM. (2000). “Interference of alkaloids with neuroreceptors and ion channels,” in Studies in Natural Products Chemistry. Ed. Ata-ur-R. (Amsterdam, Netherlands: Elsevier), 3122.

  • 192

    WinkM. (2007). “Molecular modes of action of cytotoxic alkaloids: from DNA intercalation, spindle poisoning, topoisomerase inhibition to apoptosis and multiple drug resistance,” in The Alkaloids: Chemistry and Biology, vol. 64. (San Diego, USA: Academic Press), 147.

  • 193

    WinkM. (2015). Modes of action of herbal medicines and plant secondary metabolites. Medicines2, 251286. doi: 10.3390/medicines2030251

  • 194

    WinkM. (2020). Evolution of the angiosperms and co-evolution of secondary metabolites, especially of Alkaloids. Reference Series in Phytochemistry. Co-Evolution of Secondary Metabolites (Cham, Switzerland: Springer Nature).

  • 195

    WongI. L.WangB. C.YuanJ.DuanL. X.LiuZ.LiuT.et al. (2015). Potent and nontoxic chemosensitizer of P-glycoprotein-mediated multidrug resistance in cancer: synthesis and evaluation of methylated epigallocatechin, gallocatechin, and dihydromyricetin derivatives. J. Med. Chem.58, 45294549. doi: 10.1021/acs.jmedchem.5b00085

  • 196

    WongrattanakamonP.LeeV. S.NimmanpipugP.SirithunyalugB.ChansakaowS.JiranusornkulS. (2017). Insight into the molecular mechanism of p-glycoprotein mediated drug toxicity induced by bioflavonoids: An integrated computational approach. Toxicol. Mech. Meth.27, 253271. doi: 10.1080/15376516.2016.1273428

  • 197

    WuJ. Y. C.FongW. F.ZhangJ. X.LeungC. H.KwongH. L.YangM. S.et al. (2003). Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix peucedani. Eur. J. Pharmacol.473, 917. doi: 10.1016/S0014-2999(03)01946-0

  • 198

    XuD.LuQ.HuX. (2006). Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Canc. Lett.243, 274280. doi: 10.1016/j.canlet.2005.11.031

  • 199

    YeJ.ZhengY.LiuD. (2009). Reversal effect and its mechanism of ampelopsin on multidrug resistance in K562/ADR cells. China J. Chin. Materia Med.34, 761765.

  • 200

    YooH. H.LeeM.ChungH. J.LeeS. K.KimD. H. (2007a). Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J. Agr. Food Chem.55, 76207625. doi: 10.1021/jf070893f

  • 201

    YooH. H.LeeM.LeeM. W.LimS. Y.ShinJ.KimD. H. (2007b). Effects of Schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. Planta Med.53, 444450. doi: 10.1055/s-2007-967178

  • 202

    YoshidaN.TakagiA.KitazawaH.KawakamiJ.AdachiI. (2005). Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli fructus. Toxicol. Appl. Pharmacol.209, 167173. doi: 10.1016/j.taap.2005.04.001

  • 203

    YouM.MaX.MukherjeeR.FarnsworthN. R.CordellG. A.KinghornA. D.et al. (1994). Indole alkaloids from Peschiera laeta that enhance vinblastine-mediated cytotoxicity with multidrug-resistant cells. J. Nat. Prod.57, 15171522. doi: 10.1021/np50113a007

  • 204

    YouM.WickramaratneD. M.SilvaG. L.ChaiH.ChagwederaT. E.FarnsworthN. R.et al. (1995). (-)-Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells. J. Nat. Prod.58, 598604. doi: 10.1021/np50118a021

  • 205

    ZhangS.MorrisM. E. (2003). Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Therapeut.304, 12581267. doi: 10.1124/jpet.102.044412

  • 206

    ZhangC. C.YangJ. M.WhiteE.MurphyM.LevineA.HaitW. N. (1998). The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene16, 16171624. doi: 10.1038/sj.onc.1201658

  • 207

    ZhangS.YangX.MorrisM. E. (2004). Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res.21, 12631273. doi: 10.1023/B:PHAM.0000033015.84146.4c

  • 208

    ZhangS.WangX.SagawaK.MorrisM. E. (2005). Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (–/–) mice. Drug Metabol. Dispos.33, 341348. doi: 10.1124/dmd.104.002501

  • 209

    ZhangY.LiuX.ZuoT.LiuY.ZhangJ. H. (2012). Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein. Med. Oncol.29, 534538. doi: 10.1007/s12032-011-9950-8

  • 210

    ZhouN.LiJ.LiT.ChenG.ZhangZ.SiZ. (2017). Matrine-induced apoptosis in Hep3B cells via the inhibition of MDM2. Mol. Med. Rep.15, 442450. doi: 10.3892/mmr.2016.5999

  • 211

    ZhuX.ZhangX.MaG.YanJ.WangH.YangQ. (2011). Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells. J. Pharm. Pharmaceut. Sci.14, 325335. doi: 10.18433/J3501W

  • 212

    ZhuJ.WangR.LouL.LiW.TangG.BuX.et al. (2016). Jatrophane diterpenoids as modulators of P-glycoprotein-dependent multidrug resistance (MDR): advances of structure–activity relationships and discovery of promising MDR reversal agents. J. Med. Chem.59, 63536369. doi: 10.1021/acs.jmedchem.6b00605

Summary

Keywords

cancer, ABC-transporter, drug efflux, multidrug resistance, secondary metabolites, synergism

Citation

Tinoush B, Shirdel I and Wink M (2020) Phytochemicals: Potential Lead Molecules for MDR Reversal. Front. Pharmacol. 11:832. doi: 10.3389/fphar.2020.00832

Received

20 December 2019

Accepted

20 May 2020

Published

19 June 2020

Volume

11 - 2020

Edited by

Maria José U. Ferreira, University of Lisbon, Portugal

Reviewed by

Olga Wesolowska, Wroclaw Medical University, Poland; Mariana A. Reis, University of Porto, Portugal

Updates

Copyright

*Correspondence: Michael Wink,

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics